

Jay W. Mason, M.D.  
Consultant  
Cardiovascular Drug Safety  
105 Londonderry Court  
Reno, NV 89511  
(775) 849-9910  
(775)-240-4307

## EDUCATION

Princeton University, B.A. - Biochemistry 1964-1968  
Princeton, NJ

University of Pennsylvania, School of Medicine – MD 1968-1971  
Philadelphia, PA

## TRAINING

Internship Stanford University Hospital  
1972  
Stanford, CA  
Medicine

Residency Stanford University Hospital  
1973  
Stanford, CA  
Junior Assistant Resident, Medicine

Stanford University Hospital  
1973-1974  
Stanford, CA  
Senior Assistant Resident, Medicine

Fellowship Stanford University Hospital  
1974-1976  
Stanford, CA  
Cardiology

## LICENSURE/ CERTIFICATIONS

1972 California State Medical Board  
1975 American Board of Internal Medicine, Diplomate, #04567 (June 18, 1975)  
1976 American Board of Internal Medicine, Subspecialty of Cardiovascular Disease  
Diplomate # 04567 (Oct 19, 1977)  
1983 Utah State Medical Board  
1986 Nevada State Medical Board  
1993 American Board of Internal Medicine, Subspecialty Certification in  
Cardiac Electrophysiology  
1999 Kentucky Board of Medical License – License #34942

---

**POST-DEGREE HONORS & AWARDS**

1970 National Foundation Research Award  
1981 Brotman Foundation Scholarship  
1982 Established Investigatorship of the American Heart Association  
1983 Election to American Society for Clinical Investigation  
1985 Election to Western Association of Physicians  
1986 Election to Association of University Cardiologists  
2003 Governor-elect, Kentucky Chapter of the American College of Cardiology  
2011 Honorary Degree: MD, *honoris causa*, University of Athens School of Medicine

**PROFESSIONAL EXPERIENCE**

2007-present Chief Medical Officer (Consultant)  
Spaulding Clinical Research – Milwaukee, WI

2007-present Independent Cardiac Safety Consultant

2003-2007 Covance Cardiac Safety Services, Inc - Reno, NV  
Medical Director  
Director of Research and Development

1999-present University of Utah School of Medicine - Salt Lake City, UT  
Adjunct Professor of Medicine

1999-2003 University of Kentucky College of Medicine - Lexington, KY  
Jack Gill Professor and Chair, Department of Internal Medicine

1999-2003 University of Kentucky College of Medicine - Lexington, KY  
Professor of Medicine

1983-1999 University of Utah School of Medicine - Salt Lake City, UT  
Chief, Division of Cardiology

1983-1999 University of Utah School of Medicine - Salt Lake City, UT  
Professor of Medicine

1979-1983 Stanford University School of Medicine - Stanford, CA  
Director, Cardiac Arrhythmia Study Unit

1977-1983 Stanford University School of Medicine - Stanford, CA  
Associate Director, Cardiac Catheterization Laboratories

---

1977-1983	Stanford University School of Medicine - Stanford, CA Director, Clinical Cardiac Electrophysiology Laboratory
1977-1983	Stanford University School of Medicine - Stanford, CA Assistant Professor of Medicine, Cardiology Division
1976-1977	Stanford University School of Medicine - Stanford, CA Acting Assistant Professor of Medicine, Cardiology Division
1975-1976	Stanford University School of Medicine - Stanford, CA Acting Instructor of Medicine, Cardiology Division

#### **NATIONAL RESEARCH REVIEW COMMITTEES**

1984-1988	National Institutes of Health Cardiovascular and Renal Study Section Chairman, 1986-1988
1987	National Institutes of Health, NHLBI, Clinical Trials Review Committee (ad hoc)
1987	National Institutes of Health, NHLBI, Manpower Review Committee (ad hoc)
1988-1990	American Heart Association National Research Committee, Fellowship Subgroup A
1988- 2002-2003	National Institutes of Health Reviewers Reserve (NRR) Chair, Special Review Committee, NICDR

#### **OTHER NIH SERVICE (selected)**

1982	Clinical Pharmacology of Antiarrhythmic Drugs Workshop
1983	Review Committee, SCORs in IHD (3 site visits)
1987	Peer Review Subcommittee on Clinical Trials and D&E
1988-2010	BARI Endpoints Committee
1989	Digitalis Mortality Trial (Member, DSMB)
1992-1993	NIH ICD Trial (AVID) Planning Committee
1999	Review Committee, SCORs in Sudden Death
2000	Genetics of Sudden Death, Workshop Presenter
2001-2004	Antiarrhythmic Effects of N-3 Fatty Acids (Chair, DSMB)
2001-2004	Fatty Acid Arrhythmia Trial (Chair, DSMB)
2001-2006	Periodontal Intervention in Cardiac Events (Member, DSMB)
2004-present	Resuscitation Outcomes Consortium, NHLBI (Chair, DSMB)
2005-2010	ResQ Trial, NHLBI (Member, DSMB)
2005-2006	Reviewer, Program Project Grants, NHLBI
2007-present	VEST Trial, NHLBI (Member, DSMB)
2009	Reviewer, NHLBI RC2 Grants (recovery act funds)

---

## ACADEMIC SOCIETIES AND COMMITTEES

1987-1989	American Heart Association National Scientific Sessions Program Committee
1987-1990	American Heart Association Representative, Council on Clinical Cardiology
1988-1989	American College of Cardiology National Scientific Session Program Committee
1988-1994	American College of Cardiology EP/ECG Committee
1988-2007	American College of Cardiology Electrocardiography Subcommittee (Chairman, 1993-2007)
1991-1995	American College of Cardiology Self-Assessment Program Writing Committee
1991-1992	Councilor, Western Association of Physicians
1992-1995	Secretary/Treasurer, Western Association of Physicians
1995-1996	President Elect, Western Association of Physicians
1996-1997	President, Western Association of Physicians
1997-1998	Past-President, Western Association of Physicians
1995-1998	American College of Cardiology Electrophysiology/Electrocardiography/ Pacemaker Committee
1996-2002	American College of Cardiology Educational Programs Committee
1998-2004	American College of Cardiology Educational Products Committee
2000-2009	American College of Cardiology Writing Committee on Electrocardiography
2001-2003	North American Society of Pacing and Electrophysiology Committee on Health Policy
2002-	Arizona CERT Scientific Advisory Committee
2003-2008	American Heart Association Electrocardiography Standardization Committee. Lead, Diagnostic Statement Lexicon
2003-	Drug Information Association

## EDITORIAL BOARDS

1982-1985	American Journal of Cardiology
1992-1996	International Journal of Cardiology
1989- 1995	Cardiovascular Drugs and Therapy
1993- present	Circulation
1993-1996	Annals of Internal Medicine
1997-1998	American Journal of Medicine
1999-2003	Journal of the American College of Cardiology
2007-2013	Journal of Electrocardiology

## MEMBERSHIPS

1972	American College of Physicians (Fellow, 1979)
1974	American Heart Association (Fellow, Council on Clinical Cardiology, 1978)
1974	American College of Cardiology (Fellow, 1978)
1976	National Cardiac Electrophysiology Group
1977	American Federation for Clinical Research

---

1980	American Association for the Advancement of Science
1980	Western Society for Clinical Research
1983	American Society for Clinical Investigation
1985	Western Association of Physicians
1986	Association of University Cardiologists
1990	Association of Professors of Cardiology
1996	Heart Rhythm Society (Fellow, 2004)
2003	Drug Information Association

### **FEDERAL GRANT SUPPORT**

#### As Principal Investigator

1984-1989	<u>NHLBI</u> : T32 HL07576 - Training in Cardiovascular Research, P.I.: Jay W. Mason, \$504,632 direct costs
1985-1990	<u>NHLBI</u> : R01 HL34071 - Comparison of Electrophysiologic Study to ECG Monitoring (ESVEM), P.I.: Jay W. Mason, \$5,701,538 direct costs
1986-1993	<u>NHLBI</u> : R01 HL34744 - Immunosuppressive Therapy for Biopsy-Proven Myocarditis, P.I.: Jay W. Mason, \$5,853,308 direct costs
1989-1994	<u>NHLBI</u> : T32-HL07576 - Training in Cardiovascular Research, P.I.: Jay W. Mason, \$1,542,884 direct costs
1990-1993	<u>NHLBI</u> : R01 HL34071 - Comparison of Electrophysiologic Study to ECG Monitoring (ESVEM), P.I.: Jay W. Mason, \$1,450,000 direct costs
1994-1999	<u>NHLBI</u> : T32 HL07576 - Training in Cardiovascular Research, P.I.: Jay W. Mason, \$758,980 direct costs
1995-1999	<u>NHLBI</u> : P50 HL52338 - SCOR in Sudden Death, P.I.: Jay W. Mason, \$4,369,225 direct costs
1995-1999	<u>NHLBI</u> : P50 HL52338 Sub 03 - Repolarization Changes Associated with Ventricular Arrhythmias and Sudden Death, P.I.: Jay W. Mason, Subproject P.I.: Jay W. Mason, \$698,023 direct costs
1999-2004	<u>NHLBI</u> : T32 HL07576 - Training in Cardiovascular Research, P.I.: Jay W. Mason, \$945,300 direct costs
2000-2004	<u>NHLBI</u> : P50 HL52338 Sub 06 - Therapy of Repolarization Abnormalities, P.I.: Jay W. Mason, \$1,348,857

#### Other

1985-1991	<u>NCRR</u> : M01 RR00064 Sub 0293 - General Clinical Research Center, P.I.: Current Dean, Comparison of Electrophysiologic Study to ECG Monitoring, Subproject P.I.: Jay W. Mason, approx. \$102,000 direct costs
1986-1992	<u>NCRR</u> : M01 RR00064 Sub 0381 - General Clinical Research Center, P.I.: Current Dean, Immunosuppressive Therapy for Biopsy-proven Myocarditis, Subproject P.I.: Jay W. Mason, approx. \$102,000 direct costs

- 
- 1995-1999 NHLBI: P50 HL52338 Sub 02 - Molecular and Physiologic Mechanisms of the Long QT Syndrome, P.I.: Jay W. Mason, Subproject P.I.: Mark T. Keating, Co.I.: Jay W. Mason, \$693,686 direct costs
- 1995-1999 NHLBI: P50 HL52338 Sub 04 - Electrocardiographic Measures of Ventricular Repolarization, P.I.: Jay W. Mason, Subproject P.I.: Robert L. Lux, Co.I.: Jay W. Mason, \$740,563 direct costs
- 1995-2000 NHLBI: KO8 HL02931 - Differentiation of Sudden Death Mechanisms, P.I.: Melinda L. Marks, Principal Sponsor: Jay W. Mason, \$435,421 direct costs
- 2000-2004 NHLBI: P50 HL52338 Sub 05 - Prognostic Value of Repolarization Measures, Coinvestigator: Jay W. Mason, \$1,192,334
- 2000-2004 NHLBI: P50 HL52338 Core 01 - Prognostic Value of Repolarization Measures, Coinvestigator: Jay W. Mason, \$247,619

#### **PEER REVIEWED ARTICLES**

1. Bonner JT, Barkely DS, Hall EM, Konijn TM, Mason JW, O'Keefe G, Wolfe PB: Acrasin, acrasinase, and the sensitivity to acrasin in dictyostelium discoideum. *Dev Biol* 20:72-87, 1969.
2. Mason JW, Rasmussen H, Dibella F: 3'5' AMP and Ca<sup>2+</sup> in slime mold aggregation. *Exp Cell Res* 67:156-160, 1971.
3. Rider AK, Copeland JG, Hunt SA, Mason JW, Specter MJ, Winkle RA, Bieber CP, Billingham ME, Dong EJ, Griep RB, Schroeder JS, Stinson EB, Harrison DC, Shumway NE: The status of cardiac transplantation. *Circulation* 52:531-539, 1975.
4. Mason JW, Stinson EB, Hunt SA, Schroeder JS, Rider AK: Infections after cardiac transplantation: Relation to rejection therapy. *Ann Intern Med* 85:69-72, 1976.
5. Mason JW, Stinson EB, Harrison DC: Autonomic nervous system and arrhythmias: Studies in the transplanted denervated human heart. *Cardiology* 61:75-87, 1976.
6. Mason JW, Rossen RM, Colby T, Harrison DC: Bacterial endocarditis after cardiac catheterization. *Chest* 70:293-296, 1976.
7. Billingham ME, Bristow MR, Mason JW, Friedman M: Endomyocardial biopsy findings in adriamycin-treated patients. *Proc Am Soc Clin Oncology* 17:281, 1976.
8. Ricci DR, Rider AK, Mason JW: Recurrent tachyarrhythmia associated with a bifocal demand pacemaker. *Chest* 72:120-123, 1977.

- 
9. Copeland JG, Griep RB, Bieber CP, Billingham ME, Schroeder JS, Hunt SA, Mason JW, Stinson EB, Shumway NE: Successful retransplantation of the human heart. *J Thorac Cardiovasc Surg* 73:242-247, 1977.
  10. Mason JW, Winkle RA, Rider AK, Stinson EB, Harrison DC: The electrophysiologic effects of quinidine in the transplanted human heart. *J Clin Invest* 59:481-489, 1977.
  11. Mason JW, Winkle RA, Ingels HB, Daughters GT, Harrison DC, Stinson EB: Hemodynamic effects of intravenously administered quinidine on the transplanted human heart. *Am J Cardiol* 40:99-104, 1977.
  12. Mason JW, Myers RW, Alderman EL, Stinson EB, Goris ML, Kriss JP: Technetium-99m pyrophosphate myocardial uptake in patients with stable angina pectoris. *Am J Cardiol* 40:1-5, 1977.
  13. Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. *Am J Surg Pathol* 1:17-23, 1977.
  14. Mason JW, Billingham ME, Friedman JP: Methysergide-induced heart disease: A case of multivalvular and myocardial fibrosis. *Circulation* 56:889-890, 1977.
  15. Stemple DR, Hall RJ, Mason JW, Harrison DC: Electrophysiologic effects of edrophonium in the innervated and the transplanted denervated human heart. *Br Heart J* 40:644-649, 1978.
  16. Anderson JL, Mason JW: Successful treatment by overdrive pacing of recurrent quinidine syncope due to ventricular tachycardia. *Am J Med* 64:715-718, 1978.
  17. Mason JW, Winkle RA, Meffin PJ, Harrison DC: Electrophysiologic effects of acebutolol. *Br Heart J* 40:35-40, 1978.
  18. Mason JW, Spector MJ, Ingels NB, Daughters GT, Ferris AC, Alderman EL: Haemodynamic effects of acebutolol. *Br Heart J* 40:29-34, 1978.
  19. Bristow MR, Mason JW, Billingham ME, Daniels JR: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. *Ann Intern Med* 88:168-175, 1978.
  20. Anderson JL, Mason JW, Winkle RA, Meffin PJ, Fowles RE, Peters F, Harrison DC: Clinical electrophysiologic effects of tocainide. *Circulation* 57:685-691, 1978.

- 
21. Mason JW: Techniques for right and left ventricular endomyocardial biopsy. *Am J Cardiol* 41:887-892, 1978.
  22. Ingham RE, Mason JW, Rossen RM, Goodman DJ, Harrison DC: Electrophysiologic findings in patients with idiopathic hypertrophic subaortic stenosis. *Am J Cardiol* 41:811-816, 1978.
  23. Billingham ME, Mason JW, Bristow MR, Daniels JR: Anthracycline cardiomyopathy monitored by morphological changes. *Cancer Treat Rep* 62:865-872, 1978.
  24. Mason JW, Bristow MR, Billingham ME, Daniels JR: Invasive and noninvasive methods of assessing adriamycin cardiotoxicity in man: Superiority of histopathologic assessment using endomyocardial biopsy. *Cancer Treat Rep* 62:857-864, 1978.
  25. Bristow MR, Billingham ME, Mason JW, Daniels JR: Clinical spectrum of anthracycline antibiotic cardiotoxicity. *Cancer Treat Rep* 62:873-880, 1978.
  26. Benjamin RS, Mason JW, Billingham ME: Cardiac toxicity of adriamycin-DNA complex and rubidazone: Evaluation by electrocardiogram and endomyocardial biopsy. *Cancer Treat Rep* 62:935-939, 1978.
  27. Ricci DR, Orlick AE, Reitz BA, Mason JW, Stinson EB, Harrison DC: Depressant effect of digoxin on atrioventricular conduction in man. *Circulation* 57:898-903, 1978.
  28. Lorell B, Alderman EL, Mason JW: Cardiac sarcoidosis: Diagnosis with endomyocardial biopsy and treatment with corticosteroids. *Am J Cardiol* 42:143-146, 1978.
  29. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC: Early anthracycline cardiotoxicity. *Am J Med* 65:823-832, 1978.
  30. Mason JW, Koch FH, Billingham ME, Winkle RA: Cardiac biopsy evidence for a cardiomyopathy associated with symptomatic mitral valve prolapse. *Am J Cardiol* 42:557-562, 1978.
  31. Mason JW, Winkle RA: Electrode-catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy for recurrent ventricular tachycardia. *Circulation* 58:971-985, 1978.
  32. Harrison DC, Mason JW, Schroeder JS, Stinson EB: Effects of cardiac denervation on cardiac arrhythmias and electrophysiology. *Br Heart J* 40 (suppl):17-23, 1978.



- 
33. Sami M, Mason JW, Peters F, Harrison DC: Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agent. *Am J Cardiol* 44:526-532, 1979.
  34. Harrison DC, Mason JW: Effects of catecholamines and adrenergic innervation on cardiac conduction and arrhythmias. *J R Soc Med Symp* 8:17-30, 1979.
  35. Motta J, Guilleminault C, Billingham ME, Barry WH, Mason JW: Cardiac abnormalities in myotonic dystrophy: Electrophysiologic and histopathologic studies. *Am J Med* 67:467-473, 1979.
  36. Sami M, Mason JW, Oh G, Harrison DC: Canine electrophysiology of encainide, a new antiarrhythmic drug. *Am J Cardiol* 43:1149-1154, 1979.
  37. Mason JW, Strefling A: Small vessel disease of the heart resulting in myocardial necrosis and death despite angiographically normal coronary arteries. *Am J Cardiol* 44:171-176, 1979.
  38. Mason JW, Myers RW, Goris ML, Doherty P, Alderman EL, Kriss JP: Reliability and reproducibility of interpretation of technetium 99m pyrophosphate myocardial scintigrams. *Clin Cardiol* 2:446-449, 1979.
  39. Mason JW: Evidence for a unidirectional retrograde communication between distal His bundle and the atria. *Br Heart J* 43:600-604, 1980.
  40. Mason JW: Overdrive suppression in the transplanted heart: Effect of the autonomic nervous system on human sinus node recovery. *Circulation* 62:688-696, 1980.
  41. Mason JW, Billingham ME, Ricci DR: Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. *Am J Cardiol* 45:1037-1044, 1980.
  42. Mason JW: Repetitive beating after single ventricular extrastimuli: Incidence and prognostic significance in patients with recurrent ventricular tachycardia. *Am J Cardiol* 45:1126-1131, 1980.
  43. Mason JW, Billingham ME: Endomyocardial biopsy in modern practice. *J Cardiovasc Med* 5:683-691, 1980.
  44. Mason JW, Winkle RA: Accuracy of the ventricular tachycardia induction study for predicting long-term efficacy and inefficacy of antiarrhythmic drugs. *N Engl J Med* 303:1073-1077, 1980.

- 
45. Winkle RA, Mason JW, Harrison DC: Tocainide for drug-resistant ventricular arrhythmias: Efficacy, side effects, and lidocaine responsiveness for predicting tocainide success. *Am Heart J* 100:1031-1036, 1980.
  46. Griffin JC, Mason JW, Calfee RA: Clinical use of an implantable automatic tachycardia-terminating pacemaker. *Am Heart J* 100:1093-1096, 1980.
  47. Harrison DC, Winkle RA, Sami M, Mason JW: Encainide: A new and potent antiarrhythmic agent. *Am Heart J* 100:1046-1054, 1980.
  48. Mason JW, Peters FA: Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia. *Circulation* 63:670-675, 1981.
  49. McKillop JH, McDougall IR, Goris ML, Mason JW, Reitz BA: Failure to diagnose cardiac transplant rejection with Tc-99m-Pyp images. *Clin Nucl Med* 6:375-377, 1981.
  50. Griffin JC, Mason JW, Ross DL, Calfee RV: The treatment of ventricular tachycardia using an automatic tachycardia terminating pacemaker. *PACE* 4:582-588, 1981.
  51. Bristow MR, Mason JW, Billingham ME, Daniels JR: Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. *Am Heart J* 102:709-718, 1981.
  52. Winkle RA, Mason JW, Griffin JC, Ross DL: Malignant ventricular tachyarrhythmias associated with the use of encainide. *Am Heart J* 102:857-864, 1981.
  53. Jaillon P, Rubenson D, Peters F, Mason JW, Winkle RA: Electrophysiologic effects of N-acetylprocainamide in human beings. *Am J Cardiol* 47:1134-1139, 1981.
  54. Mason JW, Stinson EB, Winkle RA, Oyer PE: Mechanisms of ventricular tachycardia: Wide, complex ignorance. *Am Heart J* 102:1083-1097, 1981.
  55. Fowles RE, Mason JW: Myocarditis and endomyocardial biopsy. *Cardiovasc Rev and Rep* 2:1153-1155, 1981.
  56. Mason JW, Stinson EB, Winkle RA, Oyer PE, Griffin JC, Ross DL: Relative efficacy of blind left ventricular aneurysm resection for the treatment of recurrent ventricular tachycardia. *Am J Cardiol* 49:241-248, 1982.

- 
57. Mitchell LB, Jutzy KR, Lewis SJ, Schroeder JS, Mason JW: Intracardiac electrophysiologic study of intravenous diltiazem and combined diltiazem-digoxin in patients. *Am Heart J* 103:57-66, 1982.
  58. Anderson KP, Stinson EB, Mason JW: Surgical exclusion of focal paroxysmal atrial tachycardia. *Am J Cardiol* 49:869-874, 1982.
  59. Mason JW, Swerdlow CD, Winkle RA, Griffin JC, Ross DL, Keefe DL, Clusin WT: Programmed ventricular stimulation in predicting vulnerability to ventricular arrhythmias and their response to antiarrhythmic therapy. *Am Heart J* 103 (Part 2):633-637, 1982.
  60. Mason JW, Stinson EB, Winkle RA, Griffin JC, Oyer PE, Ross DL, Derby G: Surgery for ventricular tachycardia: Efficacy of left ventricular aneurysm resection compared with operation guided by electrical activation mapping. *Circulation* 65:1148-1155, 1982.
  61. Melvin KR, Mason JW: Endomyocardial biopsy: Its history, techniques and current indications. *J Can Med Assoc* 126:1381-1386, 1982.
  62. Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA: Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. *Cancer* 50:32-41, 1982.
  63. Freedman RA, Rothman MT, Mason JW: Recurrent ventricular tachycardia induced by an atrialsynchronous ventricular-inhibited pacemaker. *PACE* 5:490-494, 1982.
  64. Ross DL, Sze DY, Keefe DL, Swerdlow CD, Echt DS, Griffin JC, Winkle RA, Mason JW: Antiarrhythmic drug combinations in the treatment of ventricular tachycardia: Efficacy and electrophysiologic effects. *Circulation* 66:1205-1210, 1982.
  65. Echt DS, Berte LE, Clusin WT, Samuelsson RG, Harrison DC, Mason JW: Prolongation of the human cardiac monophasic action potential by sotalol. *Am J Cardiol* 50:1082-1086, 1982.
  66. Fowles RE, Mason JW: Endomyocardial biopsy. *Ann Intern Med* 97:885-894, 1982.
  67. Swerdlow CD, Blum J, Winkle RA, Griffin JC, Ross DL, Mason JW: Decreased incidence of antiarrhythmic drug efficacy at electrophysiologic study associated with use of a third extrastimulus. *Am Heart J* 104:1004-1010, 1982.
  68. Rasmussen K, Winkle R, Ross D, Griffin J, Peters F, Mason J: Antiarrhythmic efficacy of amiodarone in recurrent ventricular tachycardia evaluated by multiple electrophysiological and ambulatory ECG recordings. *Acta Med Scand* 212:367-374, 1982.

- 
69. Mason JW, Hondeghem LM, Katzung BG: Amiodarone blocks inactivated cardiac sodium channels. *Pflugers Arch* 396:79-81, 1983.
  70. Anderson KP, Stinson EB, Derby GC, Oyer PE, Mason JW: Vulnerability of patients with obstructive hypertrophic cardiomyopathy to ventricular arrhythmia induction in the operating room: Analysis of 17 patients. *Am J Cardiol* 55:811-816, 1983.
  71. Swerdlow CD, Gong G, Echt DS, Winkle RA, Griffin JC, Ross DL, Mason JW: Clinical factors predicting successful electrophysiologic-pharmacologic study in patients with ventricular tachycardia. *J Am Coll Cardiol* 1:409-416, 1983.
  72. Mason JW, Swerdlow CD, Mitchell LB: Efficacy of verapamil in chronic, recurrent ventricular tachycardia. *Am J Cardiol* 51:1614-1617, 1983.
  73. Swerdlow CD, Winkle RA, Mason JW: Determinants of survival in patients with ventricular tachyarrhythmias. *N Engl J Med* 308:1436-1442, 1983.
  74. Swerdlow CD, Yu JO, Jacobson E, Mann S, Winkle RA, Griffin JC, Ross DL, Mason JW: Safety and efficacy of intravenous quinidine. *Am J Med* 75:36-42, 1983.
  75. Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW: Amiodarone: Clinical efficacy and toxicity in 96 patients with recurrent, drug refractory arrhythmias. *Circulation* 68:88-94, 1983.
  76. Swerdlow CD, Winkle RA, Mason JW: Prognostic significance of the number of induced ventricular complexes during assessment of therapy for ventricular tachyarrhythmias. *Circulation* 68:400-405, 1983.
  77. Winkle RA, Bach SM, Echt DS, Swerdlow CD, Imran M, Mason JW, Oyer PE, Stinson EB: The automatic implantable defibrillator: Local ventricular bipolar sensing to detect ventricular tachycardia and fibrillation. *Am J Cardiol* 52:265-270, 1983.
  78. Connolly SJ, Kates RE, Lebsack CS, Echt DS, Mason JW, Winkle RA: Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. *Am J Cardiol* 52:1208-1213, 1983.
  79. Echt DS, Griffin JC, Ford AJ, Knutti JW, Feldman RC, Mason JW: Nature of inducible ventricular tachyarrhythmias in a canine chronic myocardial infarction model. *Am J Cardiol* 52:1127-1132, 1983.

- 
80. Anderson KP, Swerdlow CD, Mason JW: Entrainment of ventricular tachycardia. *Am J Cardiol* 53:335-340, 1984.
  81. Mitchell LB, Mason JW, Scheinman MM, Winkle RA, Burchell HB: Recordings of basal ventricular preexcitation from electrode catheters in patients with accessory atrioventricular connections. *Circulation* 69:233-241, 1984.
  82. Connolly SJ, Mitchell LB, Swerdlow CD, Mason JW, Winkle RA: Clinical efficacy and electrophysiology of imipramine for ventricular tachycardia. *Am J Cardiol* 53:516-521, 1984.
  83. Keren A, Gillis AM, Freedman RA, Baldwin JC, Billingham ME, Stinson EB, Simson MB, Mason JW: Heart transplant rejection monitored by signal-averaged electrocardiography in patients receiving cyclosporine. *Circulation* 70 (suppl I):I-124-129, 1984.
  84. Mason JW, Hondeghem LM, Katzung BG: Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. *Circ Res* 55:277-285, 1984.
  85. Freedman RA, Swerdlow CD, Echt DS, Winkle RA, Soderholm-Diffatte V, Mason J: Facilitation of ventricular tachyarrhythmia induction by isoproterenol. *Am J Cardiol* 54:765-770, 1984.
  86. Mason JW, Hondeghem LM: Quinidine: The electrophysiology, pharmacology, and clinical efficacy of classic cardiac antiarrhythmic agents. *Ann NY Acad Sci*, 432:162-176, 1984.
  87. Bhandari AK, Scheinman MM, Morady F, Svinarich J, Mason J, Winkle R: Efficacy of left cardiac sympathectomy in the treatment of patients with the long QT syndrome. *Circulation* 70:I018-I023, 1984.
  88. Anderson KP, Mason JW: Transient entrainment and interruption of ventricular tachycardia with rapid atrial pacing - II. *J Am Coll Cardiol* 4(5):1067, 1984.
  89. Bhandari A, Shapiro W, Morady F, Shen D, Mason J, Scheinman M: Electrophysiologic testing in patients with the long QT syndrome. *Circulation* 71:63-71, 1985.
  90. Echt DS, Shapiro M, Trusso J, Mason JW, Winkle RA: Treatment with oral lorcaïnide in patients with sustained ventricular tachycardia and fibrillation. *Am Heart J* 109:28-33, 1985.

- 
91. Freedman RA, Gillis AM, Keren A, Soderholm-Difatte V, Mason JW: Signal-averaged electrocardiographic late potentials in patients with ventricular fibrillation or ventricular tachycardia: Correlation with clinical arrhythmia and electrophysiologic study. *Am J Cardiol* 55:1350-1353, 1985.
  92. Mason JW, Stinson EB, Oyer PE, Winkle RA, Hunt S, Anderson KP, Derby GC: The mechanisms of ventricular tachycardia in humans determined by intraoperative recording of the electrical activation sequence. *Int J Cardiol* 8:163-172, 1985.
  93. Teichman SL, Waspe LE, Matos JA, Kim SG, Fisher JD and participating members of a multicenter bethanidine study: Bethanidine sulfate: Efficacy in prevention of ventricular tachyarrhythmias during programmed stimulation. Report of a multicenter study of 56 patients. *J Am Coll Cardiol* 6:510-517, 1985.
  94. Nanas JN, Mason JW, Yoshiyuki T, Chiang BY, Olsen DB. Hemodynamic effects of an abdominal aortic counterpulsation device designed from chronic used in graded heart failure. *Life Support Systems* 2:245-249, 1985.
  95. Nanas JN, Mason JW, Taenaka Y, Olsen DB: Comparison of an implanted abdominal aortic counterpulsation device with the intraaortic balloon pump in a heart failure model. *J Am Coll Cardiol* 7:1028-1035, 1986.
  96. Mason JW: Basic and clinical cardiac electrophysiology of encainide. *Am J Cardiol* 58:18c-24c, 1986.
  97. Anderson JL, Askins JC, Gilbert EM, Miller RH, Keefe DL, Somberg JC, Freedman RA, Haft LR, Mason JW, Lessem JN: Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: A double-blind, randomized, placebo-controlled evaluation of two doses. *J Am Coll Cardiol* 8:752-762, 1986.
  98. Anderson KP, Stinson EB, Block PJ, Derby G, Oyer PE, Ross DL, Popp RL, Mason JW: Epicardial mapping in patients with hypertrophic cardiomyopathy. *J Appl Cardiol* 1:285-307, 1986.
  99. Swerdlow CD, Mason JW, Stinson ED, Oyer P, Winkle R, Derby GC: Results of operations for VT in 105 patients. *J Thorac Cardiovasc Surg* 92:105-113, 1986.
  100. Freedman RA, Anderson KP, Green LS, Mason JW: Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. *Am J Cardiol* 59:168-169, 1987.

- 
101. Mason JW, Anderson KP, Freedman RA: Techniques and criteria in electrophysiologic study of ventricular tachycardia. *Circulation* 75 (suppl III): III-125-130, 1987.
  102. Rahimtoola SH, Zipes DP, Akhtar M, Burchell H, Mason JW, Myerburg R, O'Rourke R, Ruskin J, Schlant R, Surawicz B: Consensus statement of the conference on the state of the art of electrophysiologic testing in the diagnosis and treatment of patients with cardiac arrhythmias. *Circulation* 75 (suppl III): III-3-11, 1987.
  103. Mason JW: Amiodarone. *N Engl J Med* 316:455-466, 1987.
  104. Gilbert EM, Bristow MR, Mason JW: Acute hemodynamic response to low dose enoximone (MDL 17,043): An oral dose-range study. *Am J Cardiol* 60:57C-62C, 1987.
  105. Ross DL, Davis KB, Pettinger MB, Alderman EL, Killip T, Mason JW: Features of cardiac arrest episodes with and without acute myocardial infarction (CASS). *Am J Cardiol* 60:1219-1224, 1987.
  106. Anderson JL, Fowles RE, Unverferth DV, Mason JW: Immunosuppressive therapy of myocardial inflammatory disease. Initial experience and future trials to define indications for therapy. *Eur Heart J* 8 (Suppl J):263-266, 1987.
  107. Freedman RA, Swerdlow CD, Soderholm-Difatte V, Mason JW: Prognostic significance of arrhythmia inducibility or noninducibility at initial electrophysiologic study in survivors of cardiac arrest. *Am J Cardiol* 61:578-582, 1988.
  108. Phibbs B, Fleming T, Ewy GA, Butman S, Ambrose J, Gorlin R, Orme E, Mason J: Frequency of normal coronary arteriograms in three academic medical centers and one community hospital. *Am J Cardiol* 62:472-474, 1988.
  109. Freedman RA, Swerdlow CD, Soderholm-Difatte V, Mason JW: Clinical predictors of arrhythmia inducibility in survivors of cardiac arrest: Importance of gender and prior myocardial infarction. *J Am Coll Cardiol* 12:973-978, 1988.
  110. O'Connell, JB, Mason JW: Immunosuppressive therapy in experimental and clinical myocarditis. *Pathol Immunopathol Res* 7:292-304, 1988.
  111. Nanas JN, Mason JW, Riebman JB, Charitos CE, Burns GL, Olsen DB: Preclinical evaluation of the abdominal aortic counterpulsation device. *Am Heart J* 116:1003-1008, 1988.

- 
112. Orme EC, Wray RB, Barry WH, Krueger SK, Mason JW: Comparison of three techniques for percutaneous balloon aortic valvuloplasty of aortic stenosis in adults. *Am Heart J* 117:11-17, 1989.
  113. Orme EC, Wray RB, Mason JW: Balloon mitral valvuloplasty via retrograde left atrial catheterization. *Am Heart J* 117:681-683, 1989.
  114. Mason JW, Investigators: The ESVEM trial: Electrophysiologic study versus electrocardiographic monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. *Circulation* 79:1354-1360, 1989.
  115. O'Connell JB, Mason JW: Therapeutic implications of immune mechanisms in myocarditis. *Spring Semin Immunopathol* 11:43-49, 1989.
  116. ACC/AHA Subcommittee to Assess Clinical Intracardiac Electrophysiologic Studies: Guidelines for clinical intracardiac electrophysiologic studies. A Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. *J Am Coll Cardiol* 14:1827-1842, 1990.
  117. O'Connell JB, Mason JW: The applicability of results of streamlined trials to clinical practice: the myocarditis treatment trial. *Stat Med* 9:193-197, 1990.
  118. Freedman RA, Steinberg JS, for the ESVEM Investigators: Selective prolongation of QRS late potentials by sodium channel blocking antiarrhythmic drugs: relation to slowing of ventricular tachycardia. *J Am Coll Cardiol* 17:1017-1025, 1991.
  119. Narahara KA, The Western Enoximone Study Group: Oral enoximone therapy in chronic heart failure: A placebo-controlled randomized trial. *Am Heart J* 121:1471-1479, 1991.
  120. ACC/AHA Task Force - Dreifus LS, Fisch C, Gillette PC, Griffin JC, Mason JW, Parsonnet V: Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. A Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Pacemaker Implantation). *J Am Coll Cardiol* 18:1-13, 1991 and *Circulation* 84:455-467, 1991.
  121. Anastasiou-Nana MI, Menlove RL, Nanas JN, Mason JW: Spontaneous variability of ventricular arrhythmias in patients with chronic heart failure. *Am Heart J* 122:1007-1015, 1991.



- 
122. Electrophysiology/Electrophysiology Committee Members. Flowers NC, Abildskov JA, Armstrong WF, Curtis AB, Elion JL, Gillette PC, Griffin JC, Josephson ME, Kennedy HL, Lambrew CT, Mason JW, Naccarelli GV, Sheffield LT: Recommended guidelines for training in adult clinical cardiac electrophysiology. ACC Policy Statement. *J Am Coll Cardiol* 18:637-640, 1991.
  123. Bigger JT, Jr, Fleiss JL, Rolnitzky LM, Steinman RC, with data contributed by the CAPS and ESVEM Investigators: Stability over time of heart period variability in patients with previous myocardial infarction and ventricular arrhythmias. *Am J Cardiol* 69:718-723, 1992.
  124. Sharp SD, Mason JM, Bray BE: Comparison of ST depression recorded by Holter monitors and 12-lead electrocardiograms during coronary angiography and exercise testing. *J Electrocardiol* 25:323-331, 1992.
  125. The ESVEM Investigators: Determinants of predicted efficacy of antiarrhythmic drugs in the Electrophysiologic Study Versus Electrocardiographic Monitoring trial. *Circulation* 87:323-329, 1993.
  126. Mason JW for the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Investigators: A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. *N Engl J Med* 329:445-451, 1993.
  127. Mason JW for the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Investigators: A comparison of seven antiarrhythmic drugs in patients with ventricular arrhythmias. *N Engl J Med* 329:452-458, 1993.
  128. Mason JW: Implications of the ESVEM trial for use of antiarrhythmic drugs that prolong cardiac repolarization. *Am J Cardiol* 72:59F-61F, 1993.
  129. Nanas JN, Mason JW: Pharmacokinetics and regional electrophysiologic effects of intracoronary amiodarone administration. *Circulation* 91:451-461, 1995.
  130. Omoigui NA, Marcus FI, Mason JW, Hlatky MA: Cost of initial therapy in the Electrophysiologic Study Versus Electrocardiographic Monitoring trial (ESVEM). *Circulation* 91:1070-1076, 1995.
  131. Reiter MJ, Mann DE, Reiffel JE, Hahn E, Hartz V, and the ESVEM Investigators: Significance and incidence of concordance of drug efficacy predictions by Holter

- 
- recording and electrophysiologic study in the ESVEM trial. *Circulation* 91:1988-1995, 1995.
132. Anderson KP, Walker R, Dustman T, Fuller M, Mori M, for the ESVEM Investigators: Spontaneous sustained ventricular tachycardia in the Electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. *J Am Coll Cardiol* 26:489-496, 1995.
  133. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE and the Myocarditis Treatment Trial Investigators: A clinical trial of immunosuppressive therapy for myocarditis. *N Engl J Med* 333:269-275, 1995.
  134. Hahn EA, Hartz VL, Moon TE, O'Connell JB, Herskowitz A, McManus BM, Mason JW for the Myocarditis Treatment Trial Investigators: The myocarditis treatment trial: design, methods and patient enrollment. *Eur Heart J* 16 (Suppl O):162-167, 1995.
  135. Cain ME, Anderson JL, Arnsdorf MF, Mason JW, Scheinman MM, Waldo AL: Signal-averaged electrocardiography. *J Am Coll Cardiol* 27:238-249, 1996.
  136. Mason JW, Marcus FI, Bigger JT, Lazzara R, Reiffel JA, Reiter MJ, Mann D: A summary and assessment of the findings and conclusions of the ESVEM trial. *Prog Cardiovasc Dis*, 38:347-358, 1996.
  137. Reiffel JA, Reiter MJ, Freedman RA, Mann D, Huang SKS, Hahn E, Hartz V, Mason JW, and the ESVEM Investigators: Influence of holter monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial. *Prog Cardiovas Dis* 38,5:359-370, 1996.
  138. Mason JW: Immunopathogenesis and treatment of myocarditis: The United States myocarditis treatment trial. In: *Proceedings of the Fifth Antwerp-LaJolla-Kyoto Research Conference on Cardiac Function, Kyoto, Japan, December 13-15, 1995.* *J Cardiac Failure* 2(suppl 4):S173-S177, 1996.
  139. Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, Keating MT, Mason JW: Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. *Circulation* 94:1018-1022, 1996.
  140. Smith SC, Ladenson JH, Mason JW, Jaffe AS: Elevations of cardiac troponin I associated with Myocarditis. Experimental and clinical correlates. *Circulation*, 95:163-168, 1997.
  141. Hlatky MA, Boothroyd D, Johnstone I, Marcus FI, Hahn E, Hartz V, Mason JW, for the ESVEM Investigators: Long-term cost-effectiveness of alternative management

- 
- strategies for patients with life-threatening ventricular arrhythmias. *J Clin Epidemiol*, 50:185-193, 1997.
142. Reiter MJ, Karagounis LA, Mann DE, Reiffel JA, Hahn E, Vartz V, and the ESVEM Investigators: Reproducibility of drug efficacy predictions by Holter monitoring in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. *Am J Cardiol* 79:315-322, 1997.
  143. Caforio ALP, Goldman JH, Haven AJ, Baig MK, Libera LD, McKenna WJ and the Myocarditis Treatment Trial Investigators: Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. *Eur Heart J* 18:270-275, 1997.
  144. Caruso AC, Marcus FI, Hahn EA, Hartz VL, Mason JW and the ESVEM Investigators: Predictors of arrhythmic death and cardiac arrest in the ESVEM trial. *Circulation* 96:1888-1892, 1997.
  145. Anastasiou-Nana MI, Menlove RL, Mason JW for the Western Enoximone Study Group. Quantification of prevalence of asymptomatic ventricular arrhythmias in patients with heart failure. *Annals Noninvasive Electrocardiology* 2(4): 346-353, 1997.
  146. Mann DE, Hartz V, Hahn EA, Reiter MJ and the ESVEM Investigators. Effect of reproducibility of baseline arrhythmia induction on drug efficacy predictions and outcome in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. *Am J Cardiol* 80: 1448-1452, 1997.
  147. Reiffel JA, Hahn E, Hartz V, Reiter MJ for the ESVEM Investigators. Sotalol for ventricular tachyarrhythmias: Beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. *Am J Cardiol* 79:1048-1053, 1997.
  148. Mason JW, Hancock EW, Saunders DE, Schuger CD, Griffin JC, Kennedy HL, Buxton AE: American College of Cardiology Report on ECG Exam. *J Am Coll Cardiol* 29 (2):466-8, 1997.
  149. Lozano MD, Rubocki RJ, Wilson JE, McManus BM, Wisecarver JL, and the Myocarditis Treatment Trial Investigators: Human leukocyte antigen class II associations in patients with idiopathic dilated cardiomyopathy and myocarditis. *J Cardiac Failure* 3(2):97-103, 1997.
  150. The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. *The*

- 
- Bypass Angioplasty Revascularization Investigation (BARI). *Circulation* 96:1761-1769, 1997.
151. Anastasiou-Nana MI, Karagounis LA, Anderson JL, Mason JW for the ESVEM Investigators. Spontaneous variability of ventricular ectopic activity in patients with sustained ventricular tachycardia and in survivors of cardiac arrest. *Annals of Noninvasive Electrocardiology* 3(3):194-201, 1998.
  152. Sharma PP, Ott P, Hartz V, Mason JW, Marcus FI. Risk factors for tachycardia events due to antiarrhythmic drugs: experience from the ESVEM trial. *J Cardiovas Pharmacol Therapeutics* 3(4):269-274, 1998.
  153. Olshansky B, Hahn EA, Hartz VL, Prater S, Mason JW, and the ESVEM Investigators. Clinical significance of syncope in the ESVEM trial. *Am. Heart J* 137:878-886, 1999.
  154. Mason JW, Borrowman T, Love R. Dilated cardiomyopathy: problems in diagnosis and management. *Chest* 115:569-571, 1999.
  155. Olshansky B, Hartz VL, Hahn EA, Mason JW, Douglas M, and the ESVEM Investigators. Location of Death (In-Hospital or Out-of-Hospital) and Type of Death (Arrhythmic, Cardiac, Non-Cardiac) After Inducible Sustained Ventricular Tachyarrhythmias Following Syncope, Sustained Ventricular Tachycardia, or Non-Fatal Cardiac Arrest (THE ESVEM TRIAL). *Am J Cardiology* 86:846-51, 2000.
  156. Kadish AH, Buxton AE, Kennedy HL, Knight BP, Mason JW, Schuger CD, Tracy CM. ACC/AHA clinical competence statement on electrocardiography and ambulatory electrocardiography. *Circulation* 104:3169-3178, 2001.
  157. Kadish AH, Buxton AE, Kennedy HL, Knight BP, Mason JW, Schuger CD, Tracy CM. ACC/AHA clinical competence statement on electrocardiography and ambulatory electrocardiography. *J Am Coll Cardiol* 38:2091-100, 2001.
  158. Etheridge SP, Compton SJ, Tristani-Firouzi M, Mason JW. A new oral therapy for long QT syndrome: Long-term oral potassium improves repolarization in patients with *HERG* mutations. *J Am Coll Cardiol* 42:1777-1782, 2003.
  159. Lux RL, Gettes LS, Mason JW. Understanding proarrhythmic potential in therapeutic drug development: alternate strategies for measuring and tracking repolarization. *J Electrocardiol*, 39: S161-4, 2006.

- 
160. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. Myocarditis and heart failure associated with Hepatitis C virus infection. *J Card Fail* 12:293-298, 2006.
  161. Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society endorsed by the International Society for Computerized Electrocardiology. *J Am Coll Cardiol* 49:1109-1127, 2007.
  162. Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part I: The electrocardiogram and its technology: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. *Circulation* 115:1306-1324, 2007.
  163. Mason JW, Hancock EW, Gettes LS. Recommendations for the standardization and interpretation of the electrocardiogram: part II: electrocardiography diagnostic statement list: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. *Heart Rhythm* 4:413-419, 2007.
  164. Mason JW, Hancock EW, Gettes LS, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part II: electrocardiography diagnostic statement list a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society Endorsed by the International Society for Computerized Electrocardiology. *J Am Coll Cardiol* 49:1128-1135, 2007.
  165. Mason JW, Hancock EW, Gettes LS, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part II: Electrocardiography diagnostic statement list: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. *Circulation* 115:1325-1332, 2007.
  166. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. *J Electrocardiol* 40:228-234, 2007.

- 
167. Abascal VM, Zielke JC, Spady SD, Mason JW, and Whayne TF. Synopsis of an epidemiologic study of a Kentucky county in the coronary valley. *J Kentucky Med Assoc* 106:527-531, 2008.
  168. Strachan IG, Hughes NP, Poonawala MH, Mason JW, Tarassenko L. Automated QT analysis that learns from cardiologist annotations. *Ann Noninvasive Electrocardiol* 14:S9-21, 2009.
  169. Wagner G S, Macfarlane P, Wellens H, Josephson M, Gorgels A, Mirvis D M, Pahlm O, Surawicz B, Kligfield P, Childers R, Gettes L S, Bailey J J, Deal B J, Gorgels A, Hancock E W, Kors J A, Mason J W, Okin P, Rautaharju P M, van Herpen G. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. *J Am Coll Cardiol* 53: 1003-115, 2009.
  170. Wagner GS, Macfarlane P, Wellens H, Josephson M, Gorgels A, Mirvis DM, Pahlm O, Surawicz B, Kligfield P, Childers R, Gettes LS, Bailey JJ, Deal BJ, Gorgels A, Hancock EW, Kors JA, Mason JW, Okin P, Rautaharju PM, van Herpen G. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. *Circulation* 119: e262-70, 2009.
  171. Hancock EW, Deal BJ, Mirvis DM, Okin P, Kligfield P, Gettes LS, Bailey J, Childers R, Gorgels A, Josephson M, Kors JA, Macfarlane P, Mason JW, Pahlm O, Rautaharju PM, Surawicz B, van Herpen G, Wagner GS, Wellens H. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. *J Am Coll Cardiol* 53: 992-1002, 2009.
  172. Hancock EW, Deal BJ, Mirvis DM, Okin P, Kligfield P, Gettes LS, Bailey J, Childers R, Gorgels A, Josephson M, Kors JA, Macfarlane P, Mason JW, Pahlm O, Rautaharju PM,

---

Surawicz B, van Herpen G, Wagner GS, Wellens H. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. *Circulation* 119: e251-261, 2009.

173. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, Rautaharju PM, van Herpen G, Wagner GS, Wellens H. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. *J Am Coll Cardiol* 53: 976-981, 2009.
174. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, Rautaharju PM, van Herpen G, Wagner GS, Wellens H. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. *Circulation* 119: e235-240, 2009.
175. Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, van Herpen G, Wagner GS, Wellens H. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. *J Am Coll Cardiol* 53: 982-981, 2009.
176. Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, van Herpen G, Wagner GS, Wellens H. AHA/ACCF/HRS

---

recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. *Circulation* 119:e241-250, 2009.

177. Mason JW, Florian JA, Garnett CE, Moon TE, Selness DS, Spaulding RR. Pharmacokinetics and Pharmacodynamics of Three Moxifloxacin Dosage Forms: Implications for Blinding in Active-Controlled Cardiac Repolarization Studies. *J Clin Pharmacol* 50:1249-59, 2010.
178. Darpo B, Lee SK, Moon TE, Sills N, Mason JW. Oritavancin, a new lipoglycopeptide antibiotic – results from a thorough QT study. *J Clin Pharmacol* 50:895-903, 2010
179. Min SS, Turner JR, Nada A, DiMino TL, Hynie I, Kleiman R, Kowey P, Krucoff, MW, Mason JW, Phipp A, Newton-Cheh C, Porody R, Strnadova C, Targum S, Uhl K, Finkle J. Evaluation of Ventricular Arrhythmias in Early Clinical Pharmacology Trials and Potential Consequences for Later Development. *Am Heart J* 159:716-29, 2010.
180. Matsumori A, Shimada T, Hattori H, Shimada M, Mason JW. Autoantibodies against cardiac troponin I in patients presenting with myocarditis. *CVD Prev Control* 6:41-46, 2011.
181. Mason JW, Selness DS, Moon TE, O'Mahony B, Donachie P, Howell J. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. *Clin Cancer Res* 18:2913-21, 2012.
182. Christian JB, Finkle JK, Ky B, Douglas PS, Gintant GA, Gutstein D, Hockings P, Laine P, Lenihan, Mason JW, Rodriguez I, Sager P, Todaro TG, Hicks, KA, Kane R, KO SH, Lindenfeld J, Michelson E, Milligan J, Munley J, Raichlen J, Shahlaee A, Stockbridge N, Strnad C, Ye B, Turner R. Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. *Am Heart J* 164:846-55, 2012.
183. Mason JW, Moon TE: Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. *Cancer Management Res* 5:179-85, 2013.
184. Mason J, Moon T, O'Boyle E, Dietz A. A randomized, placebo-controlled, 4-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous



- 
- granisetron and moxifloxacin on QTc prolongation. *Cancer Management Res* 6:181-190, 2014.
185. Mason JW, Schwertschlag US, Klutzaritz V, Canafax DM: Electrocardiographic and cardiovascular diagnostic characteristics of patients receiving chronic opioid therapy for pain. *J Opioid Manag* 10:103-110, 2014.
  186. Rautaharju PM, Mason JW, Akiyama, T. New Age- and Sex-Specific Criteria for QT Prolongation Based on Rate Correction Formulas that Minimize Bias at the Upper Normal Limits. *Internat J Cardiol* 174:535-540, 2014.
  187. Rautaharju, P. M., Mason, J. W., Akiyama, T. Corrigendum to "New age- and sex-specific criteria for QT prolongation based on rate correction formulas that minimize bias at the upper normal limits" (*Internat J Cardiol* 2014, *IJCA* 174/3 [535-540]). *Int J Cardiol* 2015; 178:299.
  188. Mason, JW. Timing of Pre-dose Baseline Electrocardiograms in Clinical Trials: Increased Sampling Over a Prolonged Baseline Period Worsens Variance of QTc. *J Electrocardiol* 47:716-720, 2014.
  189. Lars Johannesen, Jose Vicente, Jay Mason, Carlos Sanabria, Kristin Waite-Labott, Mira Hong, Ping Guo, John Lin, Jens Stampe Soerensen, Lorian Galeotti, Jeffry A Florian, Martin Ugander, Norman Stockbridge, David G. Strauss. Differentiating Drug-Induced Cardiac Ion Channel Block on the Electrocardiogram as Related to Torsade de Pointes Risk. *Clin Pharmacol Ther*, online publication 17 September 2014. 96:549-58. doi:10.1038/clpt.2014.155
  190. Mason, JW. Automated Measurements for Individualized Heart Rate Correction of the QT Interval. *Clin Trials*, January 2015, DOI: 10.1177/1740774514566332.
  191. Rudd GD, Haverkamp W, Mason JW, Wenger T, Jay G, Hebert D, Doty P, Horstmann R. Lacosamide cardiac safety: clinical trials of patients with partial-onset seizures. *Acta Neurol Scand*: DOI: 10.1111/ane.12414.
  192. Vicente J, Johannesen L, Mason JW, Pueyo E, Stockbridge N, Straus DG. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine and verapamil. *J Am Heart Assoc*. 2015; 4: e001615 originally published April 13, 2015 doi: 10.1161/JAHA.114.001615.
  193. L. Johannesen, J. Vicente, J.W. Mason, C. Erato, C. Sanabria, K. Waite-Labott, M. Hong, J. Lin, P. Guo, W.J. Crumb, K. Blinova, D. Chan, J. Stohlman, J Florian, M. Ugander, N.

- 
- Stockbridge, D.G. Strauss. Late Sodium Current Block for Drug-Induced Long QT Syndrome: Results from a Prospective Clinical Trial. *Clinical Pharmacology and Therapeutics*, 99:214-223, 2015.
194. Mason JW, Badilini F, Vaglio M, Lux RL, Aysin B, Moon TE, Heinz B, Strachan I. A fundamental relationship between intraventricular conduction and heart rate. *J Electrocardiol* 49:362-370, 2016.
195. Mason JW, Moon, TE. Moxifloxacin increases heart rate in humans. *Antibiotics* 2017, 6, 5; doi:10.3390/antibiotics6010005
196. Johannesen L, Vicente J, Hosseini M, Mason JW, Dang Q, Stockbridge N, Straus DG, Ugander M. Detection of Drug-Induced Reverse Use Dependence and QT Variability Using Postural Maneuvers. Submitted, *Heart Rhythm*, 2015.
197. Vicente J, Johannesen L, Mason JW, Pueyo E, Stockbridge N, Strauss DG. Sex differences in drug-induced changes in ventricular repolarization. *J Electrocardiol*. 2015 Nov-Dec;48(6):1081-7. doi: 10.1016/j.jelectrocard.2015.08.004. Epub 2015 Aug 4.
198. Kontogiannis, C. D., Malliaras, K., Kapelios, C. J., Mason, J. W., Nanas, J. N. Continuous internal counterpulsation as a bridge to recovery in acute and chronic heart failure. *World J Transplant*; 2019; 6:115-24.
199. Strauss DG, Vicente J, Johannesen L, Blinova K, Mason JW, Weeke P, Behr ER, Roden DM, Woosley R, Kosova G, Rosenberg MA, Newton-Cheh C. A Common Genetic Variant Risk Score is Associated with Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study. *Circulation*, 135:1300 – 1310, 2017. DOI: <https://doi.org/10.1161/CIRCULATIONAHA.116.023980>
200. Vicente J, Johannesen L, Hosseini M, Mason JW, Sager PT, Pueyo E and Strauss DG. Electrocardiographic Biomarkers for Detection of Drug-induced Late Sodium Current Block. *PLOS ONE* 11(12): e0163619. doi:10.1371/journal.pone.0163619. Correction: *PLoS One* 2018;13 (5):e0197952
201. Mason JW, Bellibas SE, Huang NY, Sanabria CR, Darpo B. Electrocardiographic effects of a suprathreshold dose of oritavancin. *Clin Pharmacol Drug Devel* 5(6): 502-8, 2016.
202. Mason JW. Which protocol should I use: The standard ICH E14 thorough QT/QTc study or concentration-effect modelling? *Journal for Clinical Studies* 8 (6): 68-71, 2016; November 30, 2016. <http://www.jforcs.com/protocol-use-standard-ich-e14-thorough-qtqt-c-study-concentration-effect-modelling/>.

- 
203. Mason JW. Antimicrobials and QT Prolongation. *J Antimicrob Chemother* 72:1272-4, 2017. <https://doi.org/10.1093/jac/dkw591>. 04 February 2017.
  204. Mason, JM. Cardiologist's point of view: novel ECG biomarkers and in silico models for proarrhythmic risk prediction; are we ready? *J Electrocardiol* 2017; 50:825-827. DOI: 10.1016/j.jelectrocard.2017.08.011
  205. Vicente J, Zusterzeel R, Johannensen L, Mason J, Sager P, Patel V, Matta MK, Li Z, Liu J, Garnett C, Stockbridge N, Zineh I, Strauss DG. Mechanistic model-informed proarrhythmic risk assessment of drugs: Review of the 'CiPA' initiative and design of a prospective clinical validation study. *Clin Pharm Ther* October 7, 2017. DOI: 10.1002/cpt.896. 103:1:54 – 66.
  206. Kontogiannis C, Aravantinos D, Nanas I, Kapelios CJ, Maranakis S, Vakrou S, Sarchosi S, Perrea DN, Mason JW, Nanas J, Malliaras, K. Salutary effects of the PULVAD, a novel implantable counterpulsation assist device, on left ventricular mechanoenergetics *ASAIO Journal* 2018. Doi 10.1097/MAT.0000000000000838.
  207. Brockway M, Fossa A, Mason J. Comparison of Two Highly Automated ECG Algorithms for Detection of Drug-Induced Cardiac Ion Channel Block. *Clin Pharmacol Ther* 2017, DOI: 10.1002/cpt.934.
  208. Macfarlane, P. W., Mason, J. W., Kligfield, P., Sommargren, C. E., Drew, B., van Dam, P., Abacherli, R., Albert, D. E., Hodges, M. Debatable issues in automated ECG reporting. *J Electrocardiol*;2017; 50:833-840.
  209. Mason JW, Chugh R, Patel A, Gutte R, Bhatia A. Electrocardiographic effects of a supratherapeutic dose of WCK2349, a benzoquinolizine fluoroquinolone. *Clin Transl Sci* 12:47-52, 2019 (published online on: 27 November 2018. doi:10.1111/cts.12594)
  210. Vicente J, Zusterzeel R, Johannesen L, Ochoa-Jimenez R, Mason J, Sager P, Patel V, Matta MK, Liu J, Florian J, Garnett C, Stockbridge N, Strauss DG. Assessment of Multi-Ion Channel Block in a Phase-1 Randomized Study Design: Results of the CiPA Phase 1 ECG Biomarker Validation Study, *Clin Pharm Ther* 17 November 2018. <https://doi.org/10.1002/cpt.1303>

- 
211. Kinrade SA, Mason JW, Sanabria CR, Rayner CR, Bullock JM, Stanworth SH, Sullivan MT. Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study. *Clin Transl Sci* 2018; doi: 10.1111/cts.12583
  212. Brockway M, Mason J, Brockway B. Comparison of Electrocardiographic Biomarkers for Differentiating Drug-induced Single vs. Multiple Cardiac Ion Channel Block. *Clin Translational Sci* 2019;12:257-66. doi - 10.1111/cts.12596
  213. Matsumori A, Shimada T, Nakatani E, Shimada M, Tracy S, Chapman N, Drayson M, Hartz V, Mason J. Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis. *Clin Immunol* 217:108455, 2020.
  214. Matsumori A, Shimada T, Shimada M, Otani H, Drayson MT, Mason JW. Immunoglobulin Free Light Chains as Inflammatory Biomarkers of Atrial Fibrillation. *Circ Arrhythm Electrophysiol* 2020;13:e009017.
  215. Mason JW, Strauss DG, Vaglio M, Badilini F. Correction of the QRS duration for heart rate. *J Electrocardiol* 2019;54:1-4.
  216. Sanabria C, Migoya E, Mason JW, Stanworth S, Katsube T, Machida M, Narukawa Y, Nagata TD. Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects. *Clinical Therapeutics* 2019; 41(9):1724-36.
  217. De Bie J, Diemerger I, Mason JW. Comparison of PR, QRS, and QT interval measurements by seven ECG interpretation programs. *J Electrocardiol* 63: 75-82, 2020.
  218. Isart, Fernando; Mason, Jay; Isart-Infante, Fernando; Ramos, Faustino. Surface electrocardiographic (ECG) parameters of Children and Adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) in an ambulatory community pediatric center. A focus in cardiac repolarization ECG intervals. *J Child and Adolescent Psychopharmacology*. Accepted January 2021.
  219. Kallend D, Mason J, Smith PF, Bittner V, Koren M, Stoekenbroek R, Wijngaard P. An evaluation of a suprathreshold dose of Inclisiran on cardiac repolarization in healthy volunteers: A Phase I, randomized study. submitted to PLOS ONE 2022.

- 
220. Matsumori A, Shimada T, Shimada M, Otani H, Drayson MT, Mason JW. Immunoglobulin Free Light Chains as Inflammatory Biomarkers of Atrial Fibrillation. In press, *Circ Arrhy*
  221. Matsumori A, Mason JW. The new FLC biomarker for a novel treatment of myocarditis, COVID-19 disease and other inflammatory disorders. *The International Cardiovascular Forum Journal*, accepted February 5, 2022.

#### **EDITORIALS, REVIEWS, LETTERS, SYMPOSIA**

1. Rasmussen H, Kurokawa K, Mason JW, Goodman DBP: Calcium, parathyroid hormone and calcitonin. *Proc Fourth Parathyroid Conf, ICS, #234*, 1971.
2. Mason JW: Ventricular tachycardia induction in the selection of antiarrhythmic drugs. *Practical Cardiol* 4:120-137, 1978.
3. Bristow MR, Mason JW, Daniels JR: Use of the myocardial biopsy to monitor cardiotoxicity. *Letter in Cancer Treat Rep* 62:1067-1068, 1978.
4. Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. *1978 Year Book of Cancer*, 271-273, 1978.
5. Harrison DC, Mason JW, Simpson JB: Studies of the cardiac electrophysiologic and antiarrhythmic effects of acebutolol and its major metabolite, MB 16942. *Proceedings of the Symposium "Beta blockade in clinical practice: Current trends," VIIIth World Congress of Cardiology (1978)*. WA Littler, ed., Amsterdam: Excerpta Medica, 85-91, 1979.
6. Mason JW: Anthracycline cardiotoxicity: Recognition, management, and avoidance. *Compr Ther* 5:64-67, 1979.
7. Mason JW, Billingham ME: Acute inflammatory myocarditis. *Primary Cardiol* 6:18-25, 1980.
8. Mason JW: The role of surgery in the treatment of arrhythmias. *Hosp Pract* 16:66-74, 1981.
9. Mason JW, Billingham ME: Acute inflammatory myocarditis. *Physician Asst & Health Practitioner* 16-20, 1981.

- 
10. Mason, JW: Review of "The Slow Inward Current and Cardiac Arrhythmias," DP Zipes, JC Bailey, V Elharrar, eds. JAMA 247:886, 1982.
  11. Mitchell LB, Schroeder JS, Mason JW: Comparative clinical electrophysiologic effects of diltiazem, verapamil, and nifedipine: A review. Am J Cardiol 49:629-639, 1982.
  12. Fowles RE, Mason JW: Myocardial biopsy. Mayo Clin Proc 57:459-461, 1982.
  13. Winkle RA, Swerdlow CD, Mason JW: A look to the future: Outpatient placebo controlled trials of antiarrhythmic drug efficacy in patients with life-threatening ventricular arrhythmias. Symposium on New Drugs and Devices. Philadelphia: Martinus Nijhoff, 105-109, 1983.
  14. Anderson KP, Mason JW: Surgical management of ventricular tachyarrhythmias. Clin Cardiol 6:415-425, 1983.
  15. Gillis AM, Clusin WT, Mason JW: New horizons in antiarrhythmic therapy. J Cardiovasc Med 8:959-964, 1983.
  16. Bristow MR, Billingham ME, Mason JW: Adriamycin cardiotoxicity. Am J Cardiol 53:263, 1984. (Letter to the editor.)
  17. Mason JW, Anderson KP: Treatment of ventricular arrhythmias. 2. Medical Therapy. In: Perspectives in Cardiology, 1984, B Sobel, D Julian, P Hugenholtz, eds., London: Current Medical Literature, Ltd., 225-234, 1984.
  18. Anderson KP, Mason, JW: Les mecanismes de la tachycardie ventriculaire: les enseitgnements du laboratoire d'electrophysiologie. Le Journal International de Medecine, Cardiologie Mondiale, Editoriaux 12:11-19, 1984.
  19. Fowles RE, Mason JW: Role of cardiac biopsy in the diagnosis and management of cardiac disease. Prog Cardiovasc Dis, 27:153-172, 1984.
  20. Mason JW: Endomyocardial biopsy: the balance of success and failure. Circulation 71:185-188, 1985.
  21. Freedman RA, Anderson KP, Mason JW: Electrophysiologic studies in patients with ventricular tachycardia. Annu Rev Med 37:1-12, 1986.

- 
22. Anderson JL, Mason JW: Criteria for selection of patients for programmed electrical stimulation. *Circulation* 73 (suppl II): II-50-58, 1986.
  23. Anderson KP, Freedman RA, Mason JW: The electrophysiologic study--when is it appropriate? *Drug Therapy* 16(6):111-126, 1986.
  24. Anderson JL, Mason JW: Testing the efficacy of antiarrhythmic drugs. *N Engl J Med* 315:391-393, 1986 (Editorial).
  25. Mason JW: Electrophysiologic study v Holter monitoring to assess cardiac drug therapy. *J Critical Illness* 1:12, 1986.
  26. Anderson KP, Freedman RA, Mason JW: Sudden death in idiopathic dilated cardiomyopathy. *Ann Intern Med* 107:104-106, 1987 (Editorial).
  27. Mason JW: Amiodarone. *N Engl J Med* 317:453-454, 1987 (Letter).
  28. Freedman RA, Anderson KP, Mason JW: Tachycardia. In: *Conn's Current Therapy*, RE Rakel, ed., Philadelphia: W.B. Saunders Company, 198-207, 1988.
  29. Mason JW, Moon TE: Treatment of Ventricular Tachycardia. *N Engl J Med* 318:1693-1694, 1988 (Letter).
  30. Mason JW: Prediction of amiodarone-induced pulmonary toxicity. *Am J Med* 86:2-3, 1989 (Editorial).
  31. O'Connell JB, Mason JW: Diagnosing and treating active myocarditis. *West J Med* 150:431-435, 1989.
  32. Mason JW, O'Connell JB: Clinical merit of endomyocardial biopsy. *Circulation* 79:971-979, 1989.
  33. Mason JW, O'Connell JB: A model of myocarditis in humans. *Circulation* 81:1154-1156, 1990 (Editorial Comment).
  34. Mason JW: Distinct forms of myocarditis. *Circulation* 83:1110-1111, 1991 (Editorial Comment).
  35. Mason JW: Endomyocardial biopsy and the causes of dilated cardiomyopathy. *J Am Coll Cardiol* 23, 3:591-592, 1994 (Editorial Comment).

- 
36. Mason JW for the ESVEM Investigators: The treatment of ventricular tachyarrhythmias. *N Engl J Med* 330(4):287-288, 1994 (Letter).
  37. Mason JW: Predicting antiarrhythmic drug efficacy. *Hosp Pract* 29:28-35, 1994.
  38. Mason JW: The US myocarditis treatment trial: implications for treatment of myocarditis and its progression to dilated cardiomyopathy. *Proceedings of the 3rd International Symposium of Advances in Cardiology and Cardiac Surgery III*, (September 27-29, 1995)A Maresta, ed., Rimini, Italy: 21-29, 1996.
  39. Mason JW, O'Connell JB, McManus BM: Immunosuppressive therapy for myocarditis. *N Engl J Med* 333:1714. 1995 (Response to letters.)
  40. Mason JW: Arrhythmias associated with myocarditis. *Cardiac Electrophys Rev* 1:268-269, 1997.
  41. Pisani BA, Taylor DO, Mason JW: Inflammatory myocardial diseases and cardiomyopathies. *Am J Med* 102:459-469, 1997.
  42. Mason JW, Hlatky MA: Do patients prefer physiologic pacing? *N Engl J Med* 338:1147-1148, 1998.
  43. Mason JW: Efficacy and Efficacy Testing of Sotalol. *J Am Coll Cardiol* 33(1):53-54, 1999.
  44. Mason JW: Amiodarone Pulmonary Toxicity and Professor Hounsfield. *J Cardiovasc Electrophysiol* 12:437-438, 2001.
  45. Mason, JW: Mindfully Mining MUSTT. *J Am Coll Cardiol* 38:352-4, 2001.
  46. Liu PP, Mason, JW. *Advances in Understanding Myocarditis*. *Circulation* 104:1076-1082, 2001.
  47. Mason, JW: Viral Latency: A Link between Myocarditis and Dilated Cardiomyopathy. *J Mol Cell Cardio* 34:695-698, 2002.
  48. Mason, JW: Myocarditis and dilated cardiomyopathy: An inflammatory link. *Cardiovascular Research* 60:5-10, 2003.
  49. Mason, JW: The truth about shocking Ventricular Tachycardia and Ventricular Fibrillation. *J Am Coll Cardiol* 44:853-4, 2004.



- 
50. Mason, JW: Basic research on myocarditis: Superb but unrequited. *J Am Coll Cardiol*, 10.1016/j.jacc.2013.06.030, Jul 3, 2013.
  51. Mason, JW: The methadone menace. *Clin Infect Dis*, doi: 10.1093/cid/cit469, Aug 14, 2013.

### **BOOK CHAPTERS AND BOOKS**

1. Mason JW, Billingham ME, Rider AK, Harrison DC: Myocardial biopsy. In: *Clinical Cardiology*, JT Willerson, CA Sanders, eds. Volume III of *Science and Practice of Clinical Medicine*, New York: Grune and Stratton, 606-613, 1977.
2. Mason JW, Harrison DC: Electrophysiology and electropharmacology of the transplanted human heart. In: *Cardiac Arrhythmias: Electrophysiology Diagnosis and Management*. OS Narula, ed., Baltimore: Williams and Wilkins Co., 66-81, 1979.
3. Mason JW: Cardiotoxicity of quinidine and other type I antiarrhythmic agents. In: *Drug-Induced Heart Disease*. MR Bristow, ed., Amsterdam: Biomedical Press, 261-277, 1980.
4. Mason JW, Billingham ME: Myocardial biopsy. In: *Progress in Cardiology*. PN Yu, JF Goodwin, eds., Philadelphia: Lea and Febiger, 113-146, 1980.
5. Mason JW, Buda AJ, Stinson EB, Harrison DC: Surgical therapy of ventricular tachyarrhythmias in ischemic heart disease using conventional techniques. In: *Medical and Surgical Management of Tachyarrhythmias*. Heidelberg: Springer-Verlag, 177-182, 1980.
6. Stinson EB, Mason JW, Oyer PE: Surgical treatment of ventricular tachycardia. Chapter 33 in: *Cardiac Arrhythmias: A Decade of Progress*. DC Harrison, JW Mason, HA Miller, RA Winkle, eds., Boston: G.K. Hall & Co., 447-456, 1981.
7. Mason JW, Stinson EB, Derby G, Griffin JC, Winkle RA, Ross DL, Oyer PE, Harrison DC: Advantages of intraoperative activation sequence mapping for recurrent ventricular tachycardia. Chapter 39 in: *Cardiac Arrhythmias: A Decade of Progress*. DC Harrison, JW Mason, HA Miller, RA Winkle, eds., Boston: G.K. Hall & Co., 533-542, 1981.
8. Mason JW, Winkle RA, Griffin JC: Electrophysiologic-pharmacologic studies of ventricular arrhythmias: Evaluation of methods. Chapter 46 in: *Cardiac Arrhythmias: A Decade of Progress*. DC Harrison, JW Mason, HA Miller, RA Winkle, eds., Boston: G.K. Hall & Co., 631-642, 1981.

- 
9. Griffin, JC, Mason JW, Calfee RV: A programmable tachycardia terminating pacemaker for the treatment of arrhythmias. Chapter 27 in: *Cardiac Arrhythmias: A Decade of Progress*. DC Harrison, JW Mason, HA Miller, RA Winkle, eds., Boston: G.K. Hall & Co., 383-391, 1981.
  10. Winkle RA, Mason JW, Harrison DC: Tocainide for drug-resistant ventricular arrhythmias: Efficacy, side effects and lidocaine responsiveness. Chapter 19 in: *Cardiac Arrhythmias: A Decade of Progress*. DC Harrison, JW Mason, HA Miller, RA Winkle, eds., Boston: G.K. Hall & Co., 285-296, 1981.
  11. Harrison DC, Winkle RA, Sami M, Mason JW: Encainide: A new and potent antiarrhythmic agent. Chapter 22 in: *Cardiac Arrhythmias: A Decade of Progress*. DC Harrison, JW Mason, HA Miller, RA Winkle, eds., Boston: G.K. Hall & Co., 315-330, 1981.
  12. Mason JW, Winkle RA, Swerdlow CD, Rasmussen K, Ross DL, Griffin JC: Pharmacologic therapy of ventricular tachycardia and the role of electrophysiologic study. In: *Cardiac Electrophysiology Today*. A Masoni, P Alboni, eds., New York: Academic Press, 315-323, 1982.
  13. Mason, JW: Left ventricular biopsy. Chapter 3 in: *Endomyocardial Biopsy: Techniques and Applications*. JJ Fenoglio, ed., Boca Raton: CRC Press, Inc., 15-22, 1982.
  14. Mason JW, Billingham ME: Acute inflammatory myocarditis. Chapter 10 in: *Endomyocardial Biopsy: Techniques and Applications*. JJ Fenoglio, ed., Boca Raton: CRC Press, Inc., 79-85, 1982.
  15. Billingham ME, Mason JW: The role of endomyocardial biopsy in the management of acute rejection in cardiac allograft recipients. Chapter 8 in: *Endomyocardial Biopsy: Techniques and Applications*. JJ Fenoglio, ed., Boca Raton: CRC Press, Inc., 57-64, 1982.
  16. Mason JW: Indications for endomyocardial biopsy. Chapter 6 in: *Endomyocardial Biopsy: Techniques and Applications*. JJ Fenoglio, ed., Boca Raton: CRC Press, Inc., 45-50, 1982.
  17. Griffin JC, Mason JW: Clinical experience with an automatically activated tachycardia terminating pacemaker. In: *Cardiac Pacing*. GA Feruglio, ed., Orlando: Grune and Stratton, Inc., 301-306, 1982.

- 
18. Billingham ME, Bristow MR, Mason JW, Joseph LJ: Endomyocardial biopsy. In: Congestive Heart Failure, E Braunwald, MB Mock, JT Watson, eds. New York: Grune & Stratton, Inc., 237-251, 1982.
  19. Stinson EB, Mason JW: Surgical treatment of cardiac arrhythmias. Chapter 11 in: Cardiac Arrhythmias: Current Diagnosis and Practical Management. RA Winkle, ed., Menlo Park: Addison-Wesley, 323-344, 1983.
  20. Mason JW: Intracardiac electrophysiologic studies: Techniques and indications. Chapter 2 in: Cardiac Arrhythmias: Current Diagnosis and Practical Management. RA Winkle, ed., Menlo Park: Addison-Wesley, 20-45, 1983.
  21. Winkle RA, Mason JW: Ventricular arrhythmias. Chapter 10 in: Cardiac Arrhythmias: Current Diagnosis and Practical Management. RA Winkle, ed., Menlo Park: Addison-Wesley, 290-322, 1983.
  22. Mitchell LB, Mason JW: Encainide. In: New Antiarrhythmic Drugs. L Gould, ed., New York: Futura Publishing Co. Inc., 225-238, 1983.
  23. Hondeghem L, Mason JW: Agents used in cardiac arrhythmias. In: Basic & Clinical Pharmacology, BG Katzung, ed., Los Altos: Lange Publishing Co., 158-174, 1984.
  24. Mason JW, Swerdlow CD, Winkle RA, Ross DL, Echt DS, Anderson KP, Mitchell LB, Clusin WT: Ventricular tachyarrhythmia induction for drug selection: Experience with 311 patients. Chapter 13 in: Clinical Pharmacology of Antiarrhythmic Therapy. BR Lucchesi, JV Dingell, RP Schwartz, eds., New York: Raven Press, 229-239, 1984.
  25. Echt DS, Mason JW: Management of serious cardiac arrhythmias with drugs. Chapter 13 in: Cardiovascular Clinics: Cardiac Drug Therapy, AN Brest, CR Conti, eds., Philadelphia: FA Davis, 191-209, 1984.
  26. Swerdlow CD, Mason JW: Emergency treatment of ventricular tachycardia. Chapter 5 in: Cardiac Emergencies. MM Scheinman, ed., Philadelphia: W.B. Saunders, 89-110, 1984.
  27. Anderson KP, Mason JW: Invasive electrophysiologic techniques in the diagnosis and management of cardiac dysrhythmias. Chapter 14 in: Acute Cardiac Care. DS Das Gupta, ed., Boston: Year Book Publishers, 268-293, 1984.
  28. Mason JW: Acute myocarditis. In: Current Therapy in Cardiovascular Disease 1984-1985, NJ Fortuin, ed., Philadelphia: B.C. Decker, Inc., 90-92, 1984.

- 
29. Winkle RA, Mason JW, Kates RE, and Harrison DC: Encainide. In: Recent Developments in Cardiovascular Drugs. J Coltart, D Jewitt, eds., Edinburg, United Kingdom: Churchill-Livingstone, 102-109, 1984.
  30. Laser JA, Fowles RE, Mason JW: Endomyocardial biopsy. In: Invasive Cardiology. JS Schroeder, ed., Philadelphia: F.A. Davis Company, 141-163, 1984.
  31. Elson J, Mason JW: General concepts and mechanisms of ventricular tachycardia. In: Cardiology Clinics, Vol 4, No. 3. LN Horowitz, ed., Philadelphia: W. B. Saunders Co., 459-472, 1986.
  32. O'Connell JB, Mason JW: The roles of endomyocardial biopsy and gallium 67 scintigraphy in the assessment and treatment of active myocarditis. In: Pathogenesis of Myocarditis and Cardiomyopathy: Recent Experimental and Clinical Studies, C Kawai and WH Abelmann, eds., A Matsumori, assoc. ed. Tokyo: University of Tokyo Press, 281-292, 1987.
  33. Mason JW: Is there an ideal ventricular stimulation protocol? In: Ventricular Tachycardias from Mechanism to Therapy, E Aliot and R Lazzarza, eds., Boston: Martinus Nijhoff Publishers, 299-308, 1987.
  34. Anderson KP, Freedman RA, Mason JW: Use of antiarrhythmic drugs: General principles. In: Cardiology, WW Parmely and K Chatterjee, eds., Philadelphia: JB Lippincott Co., 1-17, 1987. Updated 1991, 6.31-6.43.
  35. Gilbert EM, Mason JW: Immunosuppressive therapy of myocarditis. In: Drug Therapy in Dilated Cardiomyopathy and Myocarditis, RS Engelmeier and JB O'Connell, eds., New York: Marcel Dekker, Inc., 233-263, 1988.
  36. Freedman RA, Mason JW: Invasive electrophysiologic study. In: Progress in Cardiology 1/2, DP Zipes and DJ Rowlands, eds., Philadelphia: Lea & Febiger, 215-236, 1988.
  37. O'Connell JB, Dec GW, Mason JW: The role of cardiac transplantation in patients with active myocarditis. In: New Concepts in Viral Heart Disease. HP Schultheiss, ed., Heidelberg: Springer-Verlag, 426-432, 1988.
  38. Mason JW, Hondeghem LM: Principles of cardiac electrophysiology. In: Textbook of Internal Medicine. WN Kelley, ed. in chief, Philadelphia: J.B. Lippincott Company, 103-110, 1989.

- 
39. Lee HR, O'Connell JB, Mason JW: Immunosuppression and beta-blockade in heart failure. In: *Cardiology Clinics. Heart Failure: Current Concepts and Management*. KT Weber, ed, Philadelphia: W.B. Saunders Company, 171-181, 1989.
  40. Rawling DA, Mason JW: Programmed electrical stimulation after acute myocardial infarction. In: *Modern Coronary Care*. GS Francis and JS, eds., Boston: Little and Brown Company, 667-687, 1990.
  41. Nappi JM, Mason JW: Quinidine. In: *Drugs for the Heart and Circulation*. FH Messerli, ed., Philadelphia: W.B. Saunders, 1193-1201, 1990.
  42. Cooper MJ, Anderson KP, Mason JW: Invasive electrophysiological studies. In: *Cardiac Electrophysiology: From Cell to Bedside*. DP Zipes and J Jalife, eds., Philadelphia: W.B. Saunders Co., 837-849, 1990.
  43. Mason JW, Anderson KP, Freedman RA, Rawling DA: Influence of underlying heart disease upon utility of electrophysiologic study. In: *Cardiomyopathy Update 3. Restrictive Cardiomyopathy and Arrhythmias*. EGJ Olsen and M Sekiguchi, eds., Tokyo: University of Tokyo Press, 161-164, 1990.
  44. JW Mason, Y Hirota, eds., *Heart and Vessels, Supplement 5, Proceedings of the International Symposium on Cardiomyopathy and Myocarditis*. Tokyo: Springer-Verlag, 1990.
  45. Freedman RA, Mason JW: Sustained ventricular tachycardia: clinical aspects. In: *Cardiac Pacing and Electrophysiology, Third Edition*. P Samet and N El-Sherif, eds., Philadelphia: W.B. Saunders Co., 247-264, 1991.
  46. Steinberg JS, Freedman RA, Bigger JT, Jr, and the ESVEM Investigators: Antiarrhythmic drug therapy and the signal-averaged electrocardiogram. In: *High-Resolution Electrocardiography*. N El-Sherif and G Turitto, eds., Mount Kisco, NY: Futura Publishing Company, Inc., 569-590, 1992.
  47. Mason JW: Cardiac arrhythmias and clinical electrophysiology. In: *Adult Clinical Cardiology Self Assessment Program*. RP Lewis, ed., American College of Cardiology, 5.3-5.31, 1993.
  48. Mason JW: Classification of cardiomyopathy. In: *Hurst's The Heart, Eighth Edition*. RC Schlant and RW Alexander, eds., New York: McGraw-Hill, 1585-1590, 1994.

- 
49. O'Connell JB, Mason JW: Inflammatory heart disease. In: Congestive Heart Failure: Pathophysiology, Diagnosis, and Comprehensive Approach to Management. JD Hosenpud and BH Greenberg, eds., New York: Springer-Verlag, 223-233, 1994.
  50. Ensley RD, Renlund DG, Mason JW: Myocarditis. In: Cardiovascular Medicine. JT Willerson and JN Cohn, eds., New York: Churchill Livingstone, 894-924, 1994.
  51. Anderson KP, Mason JW: Clinical value of cardiac electrophysiological studies. In: Cardiac Electrophysiology - From Cell to Bedside, Second Edition. DP Zipes and J Jalife, eds., Philadelphia: W. B. Saunders Company, 1133-1150, 1994.
  52. Rawling DA, Mason JW: Programmed electrical stimulation after acute myocardial infarction. In: Coronary Care, Second Edition. GS Francis and JS Alpert, eds., Boston: Little and Brown Company, 669-688, 1994.
  53. Mason JW: An interpretation of the ESVEM Study. In: Progress in Clinical Pacing. E Santini, ed., Armonk, Futura Media Services, 791-798, 1995.
  54. Mason JW: Cardiac arrhythmias and clinical electrophysiology. In: Adult Clinical Cardiology Self Assessment Program-II. RP Lewis, ed., American College of Cardiology. April, 1995.
  55. Mason JW, Buxton AE, Griffin JC, Hancock EW, Kennedy HL, Saunders DE, Schuger CD, Electrocardiography Self Assessment Program. American College of Cardiology. April, 1995.
  56. Taylor DO, Mason JW: Myocarditis. In: Cardiology. WW Parmley and K Chatterjee, eds., Philadelphia: JB Lippincott Co., 1-26, 1995.
  57. Mason JW: Immunopathogenesis and Treatment of myocarditis: The United States myocarditis treatment trial. In: Heart Failure: New Insights Into Mechanisms and Management. S Sasayama, J Ross Jr, DL Brutsaert, eds., Tokyo: Churchill Livingstone, 173-177, 1996.
  58. Mason JW: Classification of cardiomyopathy. In: Hurst's The Heart, Ninth Edition. RC Schlant, RW Alexander and V Fuster, eds., New York: McGraw-Hill, 2031-2038, 1997.
  59. Mason JW, Gettes LS, Griffin JC, Hancock EW, Kastor JA, Kron J, Saunders DE, Schuger CD, Electrocardiography Self Assessment Program-II. American College of Cardiology. November, 1997.
  60. Mason JW: Myocarditis. In: Advances in Internal Medicine, Volume 44. Schrier, Baxter, V Dzau, Fauci, eds., St. Louis: Mosby, 293-310, 1999.

- 
61. Mason JW: Electrophysiologic Diagnostic Procedures. In: Cecil Textbook of Medicine 21st Edition. L Goldman and JC Bennett, eds., Philadelphia: W.B. Saunders, 230-233, 2000.
  62. Mason JW, Trehan S, Renlund DG: Myocardial Disease: Myocarditis. In: Cardiovascular Medicine, Second Edition. JT Willerson and JN Cohn, eds., Philadelphia: W.B. Saunders, 1096-1124, 2000.
  63. Mason JW, Compton SJ: Electrical Disturbances of the Heart: Long QT Syndromes. In: Cardiovascular Medicine, Second Edition. JT Willerson and JN Cohn, eds., Philadelphia: W.B. Saunders, 1656-1664, 2000.
  64. Mason JW: The electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. In: Arrhythmia Treatment & Therapy: Evaluation of Clinical Trial Evidence RL Woosley and SN Singh, eds.:Marcel Dekker, 50-74, 2000.
  65. Mason JW: Classification of Cardiomyopathies. In: Hurst's The Heart, Tenth Edition. V Fuster, RW Alexander and RA O'Rourke, eds., New York: McGraw-Hill, 1941-1946, 2001.
  66. Mason JW: Treatment of Lymphocytic Myocarditis. In: Myocarditis: From Bench to Bedside. LT Cooper, ed., Totowa, NJ: Humana Press, 391-403, 2002.
  67. Mason JW: Myocarditis. Chapter 15.8.1 in Oxford Textbook of Medicine, fourth edition. DA Warrell, TM Cox, JD Firth, and EJ Benz, New York: Oxford University Press, volume 2, 1017-1020, 2003.
  68. Mason JW: Gene Based Therapy of Long QT Syndrome. Chapter 31 in: Cardiomyopathies and Heart Failure: Biomolecular, Infectious and Immune Mechanisms. A Matsumori, ed., Boston: Kluwer Academic Publishers, 429-438, 2003.
  69. Mason JW: Inflammation and Myocarditis. In Inflammation and Cardiac Disease. GZ Feuerstein, P Libby and DL Mann, eds, Basel: Birkhauser Verlag, 315-323, 2003.
  70. Mason JW: Electrophysiologic Diagnostic Procedures. Chapter 58 in: Cecil Textbook of Medicine 22nd Edition. L Goldman and D Ausiello, eds., Philadelphia: W.B. Saunders, 2003.

- 
71. Mason JW: Classification of Cardiomyopathies. Chapter 75 in: Hurst's The Heart, Eleventh Edition. V Fuster, RW Alexander, RA O'Rourke, eds., New York: McGraw-Hill, 1883-1888, 2004.
  72. Mason JW. Myocarditis. Chapter 59 in Cardiovascular Medicine Third Edition., JT Willerson, JN Cohn, HJJ Wellins and DR Holmes, eds., London, Springer-Verlag, 1313-49, 2007.
  73. Mason JW: Myocarditis. Chapter 16.7.1 in Oxford Textbook of Medicine, fifth edition. DA Warrell, TM Cox, and JD Firth, eds., New York: Oxford University Press, 2758-64, 2010.
  74. Mason JW: Myocarditis. Chapter 16.7.1 in Oxford Textbook of Medicine, fifth edition. DA Warrell, TM Cox, and JD Firth, eds., New York: Oxford University Press, Update 2014.
  75. Mason JW: Myocarditis. Chapter 16.7.1 in Oxford Textbook of Medicine, fifth edition. DA Warrell, TM Cox, and JD Firth, eds., New York: Oxford University Press, Update 2017.
  76. Mason JW, Schultheiss HP. Myocarditis. Chapter 16.7.1 in Oxford Textbook of Medicine, sixth edition. John Firth, Christopher Conlon, Timothy Cox, eds., New York: Oxford University Press, 2020.

#### **PUBLISHED ABSTRACTS**

1. Mason JW, Myers R, Stinson EB, Kriss JP, Alderman EL: Technetium pyrophosphate myocardial scanning in coronary artery bypass surgery. *Circulation* 52 (suppl II):II-54, 1975.
2. Mason JW, Winkle RA, Ingels NB, Rider AK, Stinson EB, Harrison DC: Quinidine's electrophysiologic and hemodynamic effects in the transplanted denervated human heart. *Am J Cardiol* 37:154, 1976.
3. Mason JW, Specter MJ, Stinson EB, Ferris A, Ingels NB, Daughters GT, Alderman EL: The hemodynamic effects of acebutolol. *Clin Res* 24:86A, 1976.
4. Billingham ME, Bristow MR, Mason JW, Friedman MA: Endomyocardial biopsy findings in adriamycin-treated patients. *Proc Am Assoc Cancer Res and ASCO* 17:28, 1976.
5. Harrison DC, Mason JW, Winkle RA: Electrophysiologic action of acebutolol. *Proceedings of the Seventh Congress of the European Society of Cardiology*, Amsterdam, June 1976.



- 
6. Ingels NB, Daughters GT, Specter MJ, Mason JW, Stinson EB, Alderman EL: Non-invasive measurement of the effect of intravenous isoproterenol on left ventricular dynamics in intact unanesthetized man. *The Physiologist* 19:238, 1976.
  7. Koch FH, Billingham ME, Rider AK, Mason JW, Cipriano PR, Hancock EW: Pathophysiology of "angina" with normal coronary angiograms. *Circulation* 53-54 (suppl II):II-23, 1976.
  8. Billingham ME, Bristow MR, Mason JW, Daniels JR: Endomyocardial biopsy evidence of radiation enhancement of adriamycin cardiotoxicity. *Circulation* 53-54 (suppl II):II-23, 1976.
  9. Bristow MR, Mason JW, Billingham ME, and Daniels JR: Endomyocardial biopsy and systolic time intervals in detection of adriamycin cardiotoxicity. *Circulation* 53-54 (suppl II):II-80, 1976.
  10. Ricci DR, Orlick AC, Reitz BA, Mason JW, Stinson EB, Harrison DC: Evidence for digoxin's direct action upon atrioventricular conduction in man. *Clin Res* 25(2):94A, 1977.
  11. Koch FH, Billingham ME, Mason JW, Cipriano PR, and Hancock EW: Pathogenesis of the click-murmur-prolapse syndrome: Biopsy evidence supporting an underlying cardiomyopathic process. *Am J Cardiol* 39:272, 1977.
  12. Billingham ME, Bristow MR, and Mason JW: Endomyocardial biopsy findings in patients treated with and without mediastinal radiation. *Lab Invest* 36:3, 1977.
  13. Motta JA, Billingham ME, Guilleminault C, Barry WH, Mason JW: Cardiac electrophysiologic and histologic studies in myotonic dystrophy. *Circulation* 56 (suppl III):III-217, 1977.
  14. Anderson JL, Mason JW, Winkle RA, Meffin PJ, Fowles RE, Peters F, Harrison DC: Clinical electrophysiologic effects of tocainide. *Am J Cardiol* 41:415, 1978.
  15. Anderson JL, Pope SE, Stinson EB, Mason JW: Protozoan infections following cardiac transplantation. *Clin Res* 26:124A, 1978.
  16. Mason JW, Bristow MR, Billingham ME, Daniels JR: Studies of the identification, characterization, and amelioration of the cardiac toxicity of adriamycin in animals and man. 17th International Congress of Hematology, July 23, 1978, Paris, France.

- 
17. Sami M, Oh G, Mason JW, and Harrison DC: The electrophysiologic effects of encainide. Annual Meeting of the Canadian Cardiovascular Society, October 17, 1978, Vancouver, Canada.
  18. Schapira JN, Meltzer RS, Alderman EL, Fitzgerald JW, Strunk BL, Popp RL, Mason JW, Barry WH: Quantitative evaluation of left atrial pressure-volume relationships in patients with aortic stenosis and atrial septal defect. *Clin Res* 26:269A, 1978.
  19. Mason JW, Ricci DR, and Billingham ME: Effective therapy for acute inflammatory myocarditis. *Am J Cardiol* 43:408, 1979.
  20. Mason JW: Function of the denervated human sinus node. *Am J Cardiol* 43:388, 1979.
  21. Sami M, Mason JW, Oh G, Harrison DC: Electrophysiology of encainide in the canine model. *Clin Res* 27:201A, 1979.
  22. Sami M, Mason JW, Peters F, Harrison DC: Clinical electrophysiology of encainide. *Clin Res* 27:201A, 1979.
  23. Mason JW, Peters F: Successful treatment of life-threatening ventricular arrhythmias with encainide. *Clin Res* 27:566A, 1979.
  24. Mason JW, Winkle RA: Arrhythmia induction in patients with recurrent ventricular tachycardia: New Findings. *Circulation* 60 (suppl II):II-24, 1979.
  25. Bristow MR, Mason JW, Billingham ME: Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. *Circulation* 60 (suppl II):II-44, 1979.
  26. Jaillon P, Rubenson D, Peters F, Kates R, Mason JW, Winkle RA: Electrophysiology of n-acetyl-procainamide in man. *Circulation* 60 (suppl II):II-63, 1979.
  27. Mason JW, Winkle RA: Experience with tocainide for treatment of ventricular arrhythmias at Stanford University Medical Center. Presented at the Tocainide Workshop, Copenhagen, November 29-30, 1979.
  28. Mason JW: Repetitive beating in response to single ventricular extrastimuli: Incidence and prognostic significance in patients with recurrent ventricular tachycardia. *Am J Cardiol* 45:407, 1980.
  29. Griffin JC, Mason JW: Clinical use of an implantable automatic tachycardia terminating pacemaker. *Clin Res* 28:117A, 1980.

- 
30. Mason JW, Peters FA: Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia. *Circulation* 62 (suppl III):III-152, 1980.
  31. Mason JW, Stinson EB: Comparison of efficacy of map-guided to blind myocardial resection for recurrent ventricular tachycardia. *Circulation* 62 (suppl III):III-263, 1980.
  32. Mason JW, Stinson EB, Ross DL, Bockemuehl K: Surgical therapy for right ventricular tachycardia. *Am J Cardiol* 47:497, 1981.
  33. Winkle RA, Mason JW, Harrison DC: Encainide. British Heart Foundation Fourth European Symposium, London, July 21-24, 1981.
  34. Echt DS, Berte LE, Clusin WT, Samuelsson RG, Harrison DC, Mason JW: Monophasic action potential effects of sotalol compared to propranolol. *Circulation* 64 (suppl IV):IV-136, 1981.
  35. Echt DS, Griffin JC, Ford AJ, Knutti JW, Feldman RC, Mason JW: The nature of inducible ventricular tachyarrhythmia in the chronic canine infarct mode. *Circulation* 64 (suppl IV):IV-217, 1981.
  36. Ross DL, Davis KA, Alderman EL, Killip T, Mason JW: Ventricular tachycardia versus fibrillation in patients with cardiac arrest: Comparison of clinical, hemodynamic and angiographic characteristics (CASS) *Circulation* 64 (suppl IV):IV-306, 1981.
  37. Mason JW, Griffin JC: Assessing patients for tachycardia terminating pacemakers. *Proc Ann Conf Eng Med Biol* 23:177, 1981.
  38. Griffin JC, Mason JW: Automatic burst pacemakers for reentrant tachycardias. *Proc Ann Conf Eng Med Biol* 23:180, 1981.
  39. Swerdlow CD, Echt DS, Winkle RA, Ross DL, Griffin JC, Mason JW: Incidence of induction and drug prophylaxis of ventricular tachyarrhythmias: Dependence on arrhythmia type. *Clin Res* 30:21A, 1982.
  40. Swerdlow CD, Yu JO, Jacobson E, Mann S, Winkle RA, Griffin JC, Ross DL, Mason JW: Safety and efficacy of intravenous quinidine. *Am J Cardiol* 49:(Part 2)1043, 1982.
  41. Mason JW: Efficacy of verapamil in recurrent ventricular tachycardia (VT). *Am J Cardiol* 49:(Part 2)1915, 1982.

- 
42. Mason JW, Stinson EB, Oyer PE, Winkle RA, Derby GC: Mapping-guided surgical therapy of refractory ventricular tachycardia (VT) due to coronary artery disease. *Am J Cardiol* 49:(Part 2)947, 1982.
  43. Mason JW, Hondeghem LM, Katzung BG: Amiodarone blocks inactivated Na<sup>+</sup> channels. *Circulation* 66 (suppl II):II-292, 1982.
  44. Swerdlow CD, Echt DS, Winkle RA, Mason JW: Determinants of survival in patients with ventricular tachyarrhythmias (VTA). *Circulation* 66 (suppl II):II-25, 1982.
  45. Swerdlow CD, Winkle RA, Mason JW: Prognostic significance of ten fewer induced beats during assessment of therapy for ventricular tachycardia (VT). *Circulation* 66 (suppl II):II-80, 1982.
  46. Swerdlow CD, Echt DS, Soderholm-Difatte V, Winkle RA, Mason JW: Limited value of programmed stimulation in patients with unsustained VT. *Circulation* 66 (suppl II):II-145, 1982.
  47. Anderson KP, Stinson EB, Derby GC, Oyer PE, Mason JW: Vulnerability to ventricular arrhythmia induction in patients with hypertrophic obstructive cardiomyopathy. *Circulation* 66 (suppl II):II-146, 1982.
  48. Freedman RA, Griffin JC, Rothman MT, Mason JW: Safety and efficacy of an implantable automatic tachycardia terminating device. *Circulation* 66 (suppl II):II-217, 1982.
  49. Echt, DS, Griffin JC, Ford AJ, Knutti JW, Mason JW: Inducible ventricular arrhythmias in chronic canine model using implanted devices. 7th International Symposium on Biotelemetry, August, 1982.
  50. Clarkson CW, Mason JW, Matsubara T, Moyer JW, Hondeghem LM: Slow inactivation in guinea pig ventricular myocardium. *Biophys J* 41:309A, 1983.
  51. Freedman RA, Swerdlow CD, Winkle RA, Mason JW: Isoproterenol facilitation of ventricular tachycardia induction. *J Amer Coll Cardiol* 1:671, 1983.
  52. Connolly SJ, Mitchell LB, Swerdlow CD, Mason JW, Winkle RA: The clinical efficacy of electrophysiology of imipramine in patients with ventricular tachycardia. *J Am Coll Cardiol* 1:671, 1983.

- 
53. Anderson KP, Stinson EB, Block P, Derby G, Oyer PE, Ross DL, Popp RL, Mason JW: Epicardial activation sequence mapping in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1:621, 1983.
  54. Echt D, Swerdlow C, Anderson K, Mitchell L, Mason J, Winkle R: Value of adding extrastimuli vs shortening drive cycle length in ventricular tachycardia induction. VIIIth World Symposium on Cardiac Pacing, Vienna, Austria, May, 1983. *PACE* 6:A-141, 1983.
  55. Griffin JC, Rothman MT, Echt DS, Freedman RA, Mason JW: Long-term followup of patients with an automatic tachycardia terminating burst pacemaker. *PACE* 6:A-142, 1983.
  56. Keren A, Gillis AM, Freedman RA, Baldwin JC, Stinson EB, Simson MB, Mason JW: Heart transplant rejection monitored by signal averaged ECG in patients receiving cyclosporin A. *Circulation* 68 (suppl III):III-151, 1983.
  57. Mason JW, Stinson EB, Oyer PE, Winkle RA, Anderson KP: Arrhythmia mechanisms and outcome in surgery for recurrent ventricular tachycardia. *Circulation* 68 (suppl III):III-176, 1983.
  58. Bhandari AK, Shapiro WA, Evans-Bell T, Morady F, Mason J, Scheinman M: Electrophysiologic studies in the long QT syndrome. *Circulation* 68 (suppl III):III-426, 1983.
  59. Bhandari AK, Morady F, Shen EN, Schwartz A, Mason J, Scheinman M: Is left cervicothoracic sympathectomy effective treatment for patients with the prolonged QT syndrome? *Circulation* 68 (suppl III):III-427, 1983.
  60. Echt DS, Shapiro M, Miller J, Mason JW, Winkle RA: Oral Lorainide for sustained ventricular tachycardia and fibrillation. *J Am Coll Cardiol* 3:475, 1984.
  61. Freedman RA, Gillis AM, Keren A, Soderholm-Difatte V, Mason JW: Signal-averaged ECG late potentials correlate with clinical arrhythmia and electrophysiology study in patients with ventricular tachycardia or fibrillation. *Circulation* 70 (suppl II):II-252, 1984.
  62. Nanas JN, Olsen DB, Hamanaka Y, Mason JW, Kolff WJ: Hemodynamic effects and biocompatibility of valveless implantable abdominal aortic counterpulsation device (AACD). *Circulation* 70 (suppl II):II-306, 1984.

- 
63. Swerdlow CD, Mason JW, Stinson ED, Oyer P, Winkle R, Derby G: Results of map-guided surgery in 103 patients with ventricular tachycardia. *J Am Coll Cardiol* 5:409, 1985.
  64. Dorian P, Ford AJ, Davy JM, Meindl JD, Mason JW, Echt DS: Induced ventricular arrhythmias in a new chronic model of canine myocardial infarction. *PACE* 8:314, 1985.
  65. Nanas JN, Mason JW, Yoshiyuki T, Chiang BY, Olsen DB: Superiority of an implanted abdominal aortic counter pulsation device designed for chronic use compared to intraaortic balloon pump. *Circulation* 72 (suppl III):III-203, 1985.
  66. Nanas JN, Mason JW, Yoshiyuki T, Chiang BY, Olsen DB: Hemodynamic effects of an implanted abdominal aortic counterpulsation device designed for chronic use on graded heart failure. To be presented at the 12th Annual Congress of the European Society for Artificial Organs, Sept. 16-19, 1985, Athens, Greece. Published in the Transactions of the ESAO.
  67. Mason JW and the Amiodarone Toxicity Study Group: Toxicity of amiodarone. *Circulation* 72 (suppl III):III-272, 1985.
  68. Freedman RA, Swerdlow CD, Soderholm-Difatte V, Mason JW: Prognostic significance of arrhythmias induced at electrophysiologic study in cardiac arrest survivors. *Circulation* 72 (suppl III):III-45, 1985.
  69. Anderson KP, Lux RL, Nussbaum JA, Mannis D, Freedman RA, Mason JW: Dissimilarity in morphology of premature ventricular complexes and ventricular tachycardia. *Circulation* 74 (suppl II):II-187, 1986.
  70. Anderson JL, Askins JC, Gilbert EM, Miller RH, Keefe DL, Somberg JC, Freedman RA, Haft LR, Mason JW, Lessem JN: A controlled multicenter evaluation of sotalol for suppression of complex ventricular arrhythmias. *Circulation* 74 (suppl II):II-311, 1986.
  71. Nanas JN, Mason JW, Taenaka Y, Riebman JB, Olsen DB: Hemodynamic effects of an implanted abdominal aortic counterpulsation device after chronic use in animals. *Circulation* 74 (suppl II):II-509, 1986.
  72. Steinberg JS, Freedman RA, for the ESVEM Investigators: The signal averaged ECG does not predict drug efficacy in sustained ventricular arrhythmias. *Circulation* 76:IV-344, 1987.

- 
73. O'Connell JB, Dec GW, Billingham ME, Goldenberg IF, Starling RC, Mudge GH, Augustine SM, Costanzo-Nodin MR, Hess ML, Hosenpud JD, Icenogle TB, Menlove RL, Mason JW: Results of cardiac transplantation in active myocarditis. *J Heart Trans*, 8:99, May 1989.
  74. Anastasiou-Nana MI, Menlove RL, Nanas JN, Mason JW, for the Western Enoximone Study Group: Spontaneous ventricular arrhythmia variability in patients with chronic heart failure. *Circulation* 80 (suppl II):II-119, 1989.
  75. Nanas JN, Anderson KP, Mason JW: Regional electrophysiological effects of intracoronary amiodarone. *Circulation* 80 (suppl II):II-328, 1989.
  76. Anderson KP, Ershler PR, Lux RL, Karwande SV, Gay WA, Urie PM, Runnels DE, Pace NL, Mason JW: Nonuniform electrical activation in idiopathic dilated cardiomyopathy. *Circulation* 80 (suppl II):II-431, 1989.
  77. McManus BM, Switzer BL, Kendall TJ, O'Connell JB, Mason JW, Myocarditis Treatment Trial Investigators: Markedly diminished natural killing and antibody-dependent cell-mediated cytotoxicity in patients with idiopathic dilated cardiomyopathy and biopsy proven myocarditis. *Circulation* 80 (suppl II):II-666, 1989.
  78. Freedman RA, Fuller MS, Steinberg JS, for the ESVEM Investigators: Effect of antiarrhythmic drugs on frequency-domain parameters of signal-averaged ECG. *J Am Coll Cardiol* 13(2):191A, 1989.
  79. Greenberg FM, Dustman TJ, Fuller MS, Lux RL, Anderson KP, ESVEM Investigators: Initiation of spontaneous sustained monomorphic ventricular tachycardia. *Circulation* 82:III-580, 1990.
  80. Sharp SD, Mason JW: Comparison of ST depression recorded by AM Holter and 12-lead electrocardiogram during coronary arteriography and exercise testing. *J Am Coll Cardiol* 17:168A, 1991.
  81. Myocarditis Treatment Trial Investigators: Incidence and clinical characteristics of myocarditis. *Circulation* 84 (suppl II):II-2, 1991.
  82. The ESVEM Investigators: Determinants of a drug efficacy prediction in the ESVEM trial: differences between electrophysiological study (EPS) and Holter monitoring (HM). *Circulation* 84 (suppl II):II-348, 1991.

- 
83. Jay W. Mason and The ESVEM Investigators: Unsustained VT as a predictor of spontaneous sustained VT in the ESVEM study. *Circulation* 84 (suppl II):II-348, 1991.
  84. Anderson KP for the ESVEM Investigators: The Electrophysiologic study versus electrocardiographic monitoring trial. 58th Annual Meeting of the German Society for Heart and Circulation Research (58 Jahrestagung der Deutschen Gesellschaft für Herz- und Kreislaufforschung) Mannheim, Germany, April 23-26, 1992.
  85. Caruso AC, Hahn EA, Marcus FI, The ESVEM Investigators. Predictors of arrhythmic death and cardiac arrest in the ESVEM study. *Circulation* 88:I-606, 1993.
  86. Omoigui N, Marcus F, Mason J, Hlatky M, for the ESVEM Investigators: Effect of clinical and technical variables on initial hospital cost in ESVEM (Electrophysiologic Study Versus Electrocardiographic Monitoring for prediction of drug efficacy in ventricular arrhythmias.) *Clinical Research* 41:121A, 1993.
  87. Omoigui N, Marcus F, Mason J, Hlatky M, for the ESVEM Investigators: Initial hospital costs in ESVEM (Electrophysiologic Study Versus Electrocardiographic Monitoring for prediction of drug efficacy in ventricular arrhythmias). *Clinical Research* 41:234A, 1993.
  88. Mendes LA, Picard MH, Dec GW, Palacios IF, Ryan TJ, Davidoff R, for the Myocarditis Treatment Trial Investigators: Left ventricular sphericity in active myocarditis. *Circulation* 88:I-599, 1993.
  89. Reiffel J, Mann D, Reiter M, Freedman R, Huang SK, Hahn EA, Hartz VL and the ESVEM Investigators: A comparison of Holter suppression criteria for declaring drug efficacy in patients with sustained ventricular tachyarrhythmias in the ESVEM trial. *J Am Coll Cardiol* 23(2) (Special Issue):279A, 1994.
  90. Reiter M, Mann D, Reiffel J, Hahn E, Hartz V, and the ESVEM Investigators: Predictive value of combined Holter monitoring (HM) and electrophysiologic testing (EP) in the ESVEM study. *J Am Coll Cardiol* 23(2) (Special Issue):279A, 1994.
  91. Reiffel JA, Reiter M, Freedman R, Mann D, Huang SKS, Hahn E, Hartz V, and the ESVEM Investigators: Did the number of premature stimuli used or the length of unsustained tachycardia induced affect the predictive accuracy of the electrophysiologic study used to guide therapy in the ESVEM trial. *PACE* 17(II):826, 1994.
  92. Hlatky MA, Boothroyd DB, Johnstone IM, Marcus FI, Hahn E, Hartz V, Mason J, for the ESVEM Investigators: Cost-effectiveness of alternative management strategies for life threatening arrhythmias in the ESVEM trial. *Circulation* 90(4):I-43, 1994.



- 
93. Hlatky MS, Boothroyd DB, Johnstone IM, Marcus FI, Hahn E, Hartz V, Mason J for the ESVEM Investigators: Long-term cost of alternative management strategies for life threatening ventricular arrhythmias in the ESVEM trial. *Circulation* 90(4):II-339, 1994.
  94. Reiter MJ, Mann DE, Reiffel JE, Karagounis LA, Hahn E, Hartz V, and the ESVEM Investigators: Reproducibility of drug efficacy prediction by Holter monitoring in the ESVEM trial. *Circulation* 90(4):I-178, 1994.
  95. Lozano L, Wisecarver JL, Rubocki RJ, Wilson JE, McManus BM, and the Myocarditis Treatment Trial Investigators: HLA-Class II associations in patients with myocarditis. *Lab Invest* 70:129A, 1994.
  96. Mendes LA, Picard MH, Dec GW, Palacios IF, Mahoney D, Davidoff R for the Myocarditis Treatment Trial Investigators: Discordance of right and left ventricular remodeling in active myocarditis. *J Am Coll Cardiol* 23(2) (Special Issue):365A, 1994.
  97. Mendes LA, Picard MH, Dec GW, Davidoff R, for the Myocarditis Treatment Trial (MTT) Investigators: Early development of sphericity in active myocarditis: Association with left ventricular volume and function. *J Am Soc Echocardiogr* 7:S3939, 1994.
  98. Anderson KP, Walker R, Dustman TJ, Fuller MS for the ESVEM Investigators: Spontaneous versus induced ventricular tachycardia in the electrophysiologic study versus electrocardiographic monitoring trial (ESVEM). *Circulation* 90(4):I-339, 1994.
  99. Anderson KP, Mori M, Lyver S, Dustman T, Fuller MS, for the ESVEM Investigators: Mode of onset of spontaneous ventricular tachycardia and outcome in the electrophysiologic study versus electrocardiographic monitoring trial (ESVEM). *Circulation* 90(4):I-178, 1994.
  100. Olshansky B, Hahn E, Hartz V and the ESVEM Investigators: Is syncope in the ESVEM trial a marker of cardiac arrest or all cause mortality? *Circulation* 90(4):I-456, 1994.
  101. Anderson KP, Mori M, Lyver S, Dustman T, Fuller MS, for the ESVEM Investigators: Clinical characteristics and outcome of patients with ventricular tachycardia on the baseline Holter recording in the electrophysiologic study versus electrocardiographic monitoring trial (ESVEM). *Circulation* 90(4):I-339, 1994.
  102. Reiffel JA, Hahn E, Hartz V and the ESVEM Investigators: Was the superiority of sotalol in the ESVEM trial due to its beta blocking effects? *PACE* 18, 4 (II):811, 1995.

- 
103. Olshansky B, Hartz V, Hahn E, Mason JW and the ESVEM Investigators: Out-of-hospital versus in-hospital death I the ESVEM trial. *J Am Coll Cardiol (Special Issue)*:314A, Feb 1995.
  104. Compton SJ, Lux RL, Ramsey MR, Strellich KT, Sanguinetti MC, Keating MT, Mason JW: Gene-derived therapy in inherited long QT syndrome: correction of abnormal repolarization by potassium. *PACE* 19, 4 (II):642, 1996.
  105. Anderson KP, Mori M, Farig S, Gottipaty V and ESVEM Investigators: Improved Outcome in patients with ischemic heart disease assigned to electrophysiologic study in ESVEM trial. *PACE* 19:618, 1996.
  106. Li C, Shusterman V, Gottipaty V, Fahrig S, Anderson KP for the ESVEM Investigators: Changes in the energy distribution of heart rate variability in patients with chronic sympathetic predominance. *PACE* 20(II):1104, 1997.
  107. Konety S, Shusterman V, Shah SI, Gottipaty V, Fahrig S, Anderson KP for the ESVEM Investigators: Dissociation in QT-RR Relationship. *PACE* 20(II):1112, 1997.
  108. Shusterman V, Aysin B, Gottipaty V, Fahrig S, Anderson KP for the ESVEM Investigators: Physiological saturation in the markers of sympathetic activity preceding spontaneous sustained ventricular tachycardia. *PACE* 20(II):1158, 1997.
  109. Aysin B, Shusterman V, Grave I, Gottipaty V, Fahrig S, Anderson KP for the ESVEM Investigators: Differences in circadian variations of ventricular tachycardia and premature ventricular complexes. *J Am Coll Cardiol* 29:293A, 1997.
  110. Shusterman V, Young L, Aysin B, Gottipaty V, Fahrig S, Anderson KP for the ESVEM Investigators: Heart rate variability preceding spontaneous ventricular tachycardia. *J Am Coll Cardiol* 29:472A-473A, 1997.
  111. Anderson KP, Shusterman V, Aysin B, Fahrig S, Gottipaty V, ESVEM Investigators. Autonomic nervous system activity before PVC-triggered and non PVC-triggered spontaneous sustained ventricular tachycardia. *Circulation* 96(8):I-24, 1997.
  112. Konety S, Shusterman V, Shah SI, Gottipaty V, Fahrig S, Anderson KP, for the ESVEM Investigators. Dissociation in QT-RR relationship preceding sustained ventricular tachycardia. Presented at the Annual Scientific Sessions of the North American Society for Pacing and Electrophysiology, New Orleans, Louisiana, 1997.

- 
113. Shusterman V, Aysin B, Beigel A, Brode S, Fahrig S, Gottipaty V, Schwartzman D, Weiss R, Anderson KP, for the ESVEM Investigators. Do slow variations in heart rate predict spontaneous initiation of ventricular tachycardia? *PACE* 21(II):948, 1998.
  114. Shusterman V, Li C, Aysin B, Brode S, Fahrig S, Gottipaty V, Schwartzman D, Weiss R, Anderson KP, for the ESVEM Investigators. Circadian changes in the energy distribution of wavelet-transformed heart rate variability. *PACE* 21(II):887, 1998.
  115. Compton SJ, Zhang L, Vincent GM, Timothy KW, Sanguinetti MC, Green LS, Lux RL, Mason JW. Adrenergic Ca<sup>++</sup> and K<sup>+</sup> Currents in Patients with KVLQT1 Mutations. *Circulation* 98(17): I-776, 1998.
  116. Zhang L, Compton SJ, Antzelevitch C, Timothy KW, Vincent GM, Mason JW. Differential Response of QT and QU Intervals to Adrenergic Stimulation in Long QT Patients With I<sub>Ks</sub> Defects. *JACC* 33(2A): 138A, 1999.
  117. Mason J, Compton S, Shepperd T, Pursley M, Burkhardt D. Gene-based Therapy of Inherited LQT Syndrome. *Cardiovasc Drugs and Ther* 15(1): 27, 2001.
  118. Mason J. The Diagnosis of Myocarditis: Past, Present and Future. *Cardiovasc Drugs and Ther* 15(1): 37, 2001.
  119. Etheridge SP, Compton SJ, Pursley M, Burkhardt J, Shepperd T, Mason JW. Potassium shortens QTc in long QT patients with I<sub>Kr</sub> defects. *PACE* 24:606, 2001.
  120. Nadira Rambihar, Philip Jong, Peter R. McLaughlin, Jack Butany, Jay W. Mason, Peter P. Liu. Comparing Long-Term Survival and Frequency of Heart Transplantation in Patients With Suspected Versus Biopsy-Proven Myocarditis: A 15-Year Prospective Follow-Up. *J Am Coll Cardiol*, 41:172A, 2003.
  121. Matsumori A, Chapman NM, Tracy SM, Mason JW. Hepatitis C virus infection as a cause of myocarditis and heart failure. *Circulation*. 2004; 110 (supp III): 366
  122. Matsumori A, et al. N-terminal pro-brain natriuretic peptide as a marker of myocardial injury in patients with heart failure due to myocarditis and in health screening of individuals infected with hepatitis C virus. *Circulation*, 112:II-600, 2005.
  123. Mason JW, Morris S. Acute and Chronic Effects of PTH(1-84) on Heart Rate and Cardiac Repolarization in Postmenopausal Women with Osteoporosis. *J Bone Miner Res*, 21 (Suppl 1), 2006.  
(<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={D78055BD-2F22-4D28-A25F-B610F9214BB4}&SKey={701AD50E-365F-491F-A023->

---

17AA305FFCAD}&MKey={FC197A55-D8DD-4F3D-9994-290B64584CCB}&AKey={D0C01D4F-E23B-45E2-ACD4-0AF8AC866B8B}

124. Mason JW, Strachan I, Bloomfield DS, Tarrasenko L. BioQT Improves Standard Deviation of QTc in Definitive QT Studies. Drug Information Association, Prague, 2007.
125. Hans-Peter Guler, Jianke Li, A. Marie O'Farrell, Julie M. Cherrington, David Carter, Jay W. Mason, Teresa Boyea. Dutogliptin, a DPP4 inhibitor, does not affect cardiac repolarization in a thorough QT/QTc study in healthy subjects. Diabetes, June supplement, 2010.
126. Howell JD, Mason J. O'Mahony B, Donachie P. Cardiac safety of a granisetron transdermal system in the treatment of chemotherapy-induced nausea and vomiting. 2011 ASCO Annual Meeting electronic publication. Abstract number e19601. URL: [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=102&abstractID=81879](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81879).
127. Guillory G, Howell J, Mason JW, Donachie P. Cardiac safety of a granisetron transdermal system in the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract 18 (5):14, 2012
128. S.E. Bellibas, N.Y Huang, C. Sanabria, K. Fusaro, S. Good, B. Darpo, J. Mason. The Effect of Supratherapeutic Doses of Oritavancin on ECG intervals in Healthy Volunteers: Results from a Randomized, Double-Blind, Placebo- and Moxifloxacin-Controlled TQT Study. Abstract A-1307, presented at ICAAC 2014 (54<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, 2014, Washington, DC.
129. Jose Vicente, Lars Johannesen, Richard Afoakwa, Esther Pueyo, Norman Stockbridge, Jay W. Mason, David G. Strauss. T-wave morphology assessment in a randomized double-blind crossover study of four hERG potassium channel blocking drugs. In press. Circulation, 2014.
130. Johannesen L, Vicente J, Mason JW, Florian J, Galeotti L, Ugander M, Stockbridge N, Strauss DG. Improving proarrhythmic risk assessment of drugs: Combined retrospective and prospective clinical studies of 42 drugs. FDA Science Forum, 2015.
131. Vincent J, Johannesen L, Mason JW, Crumb WJ, Pueyo E, Stockbridge N, Strauss D. Comprehensive analysis of novel electrocardiographic device algorithms for differentiating arrhythmic risk. FDA Science Forum, 2015.

- 
132. Vicente J, Johannesen L, Mason JW, Pueyo E, Stockbridge N, Strauss DG. Sex differences in drug-induced changes in ventricular repolarization. ISCE, 4/13/15 (poster contest winner).
  133. Wang Y, Haiyan L, Li Y, Guo S, Morganroth J, Mason JW, Liu J, Stockbridge NL. Lacin of inter-ethnic difference in QT-susceptibility to moxifloxacin: Two independent QTS studies in Caucasian and Asian populations. 51<sup>st</sup> Annual DIA Meeting, Washington DC, June 2015.
  134. Strauss DG, Vicente J, Hosseini M, Crumb W, Mason, JW, Stockbridge, N, Johannesen. In Vitro to Clinical Translation to Improve Proarrhythmia Risk Assessment. Safety Pharmacology Society, September 28, 2015, Prague.
  135. Johannesen L, Vicente J, Mason JW, Florian J, Galeotti L, Ugander M, Stockbridge N, Strauss D. Improving Proarrhythmic Risk Assessment of Drugs: Combined Retrospective and Prospective Clinical Studies of 42 Drugs. FDA Science Forum Brochure, 2015, 188.
  136. Vicente J, Johannesen L, Mason JW, Crumb WJ, Pueyo E, Stockbridge N, Strauss D. Comprehensive Analysis of Novel Electrocardiographic Device Algorithms for Differentiating Arrhythmic Risk. FDA Science Forum Brochure, 2015, 195.
  137. Mason JW, Chugh R, Lakdavalala F, Bhatia A. Electrocardiographic Effects of WCK 2349. ECCMID, April 9-12, 2016, Amsterdam.  
[https://www.escmid.org/escmid\\_publications/escmid\\_elibrary/?q=mason&tx\\_solr%5Bfilter%5D%5B0%5D=main\\_filter\\_escmid%253Atrue&tx\\_solr%5Bfilter%5D%5B1%5D=author%253AJay%2BMason](https://www.escmid.org/escmid_publications/escmid_elibrary/?q=mason&tx_solr%5Bfilter%5D%5B0%5D=main_filter_escmid%253Atrue&tx_solr%5Bfilter%5D%5B1%5D=author%253AJay%2BMason)
  138. Hellowell J, Zeng D, Patel K, Jochelson P, Blair C, Mason J, Belardinelli L. Eleclazine (GS-6615) attenuates QTc prolongation by dofetilide in healthy subjects. 2016 HRS abstract accepted for presentation.
  139. Matsumori A, Shimada M, Shimada T, Tracy SM, Chapman NM, Hartz VL, Drayson MT, Mason JW. Elevated serum immunoglobulin free light chains in heart failure in the myocarditis treatment trial. 2016 ISCHF December 2016.
  140. Mason JW, Hugentobler E, Formella AE, Pope LE. Cardiac safety and QT intervals with DM/Q treatment: A review of clinical trial data. APA annual meeting, San Diego, May 20-24, 2017, submitted; resubmitted to NEI 2017 (Accepted for Neuroscience Education Institute, Colorado Springs, CO, November 8-12).

- 
141. Anand P, Mason J, Shakeri-Nejad K, Weitzman R, Wright A, Pandhi S and Legangneux E. Evaluation of effects of the novel AT2R antagonist EMA401 on electrocardiographic and hemodynamic variable in health subjects. Accepted for EFIC2017 (European Pain Federation Copenhagen September 6-9).
  142. Jay W Mason, Gary T Elliott, Suzanne J Romano, Boaz Mendzelevski, Robin Allgren, Mireille Gillings, and Denis Roy. HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation - Phase 1 Study Results. Abstract 11495, 11 Nov 2019Circulation. 2019;140
  143. Sabrina Paganoni, Steven E. Arnold, Suzanne Hendrix, Jessie Nicodemus-Johnson, Samuel P. Dickson, Newman Knowlton, Jamie Timmons, Mabelle Manuel, Shide Badri, Patrick D. Yeramian, Jay W. Mason, Merit Cudkowicz. Safety of a Fixed-Dose Cof ormulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis and Alzheimer's Disease: Integrated Clinical Trials Experience. Abstract 131, AAN Annual Meeting , 2022